

(19)



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11)

EP 1 034 278 B1

(12)

EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention
of the grant of the patent:
05.10.2005 Bulletin 2005/40

(21) Application number: **98960642.1**

(22) Date of filing: **02.12.1998**

(51) Int Cl.⁷: **C12N 15/53, C12N 15/55,
C12N 15/60, C12P 7/20,
C12P 7/18, C12N 1/15,
C12N 1/19, C12N 1/21,
C12N 9/04, C12N 9/16,
C12N 9/88**

(86) International application number:
PCT/US1998/025551

(87) International publication number:
WO 1999/028480 (10.06.1999 Gazette 1999/23)

(54) METHOD FOR THE PRODUCTION OF GLYCEROL BY RECOMBINANT ORGANISMS

HERSTELLUNGSMETHODE VON GLYCERIN MITTELS REKOMBINANTEN ORGANISMEN

PROCEDE DE PRODUCTION DE GLYCEROL PAR DES ORGANISMES DE RECOMBINAISON

(84) Designated Contracting States:
AT BE CH DE FR GB IE IT LI NL SE

(30) Priority: **02.12.1997 US 982783**

(43) Date of publication of application:
13.09.2000 Bulletin 2000/37

(73) Proprietors:
• **E.I. DU PONT DE NEMOURS AND COMPANY**
Delaware 19898 (US)
• **GENENCOR INTERNATIONAL, INC.**
New York 14618 (US)

(72) Inventors:
• **NAIR, Ramesh, V.**
Wilmington, DE 19809 (US)
• **PAYNE, Mark, S.**
Wilmington, DE 19808 (US)
• **TRIMBUR, Donald, E.**
Redwood City, CA 94601 (US)
• **VALLE, Fernando**
Burlingame, CA 94010 (US)

(74) Representative: **Carpmaels & Ransford**
43 Bloomsbury Square
London WC1A 2RA (GB)

(56) References cited:

WO-A-96/35795	WO-A-96/35796
WO-A-96/35799	WO-A-97/07199
WO-A-98/21339	WO-A-98/21340
WO-A-98/21341	FR-A- 2 735 145

- **WANG H.-T. ET AL.:** "Cloning, sequence, and disruption of *Saccharomyces diastaticus* DAR1 gene encoding a glycerol-3-phosphate dehydrogenase." *JOURNAL OF BACTERIOLOGY*, vol. 176, no. 22, November 1994, pages 7091-7095, XP000563880 cited in the application
- **NORBECK J. ET AL.:** "Purification and characterization of two isoenzymes of DL-glycerol-3-phosphatase from *Saccharomyces cerevisiae*." *JOURNAL OF BIOLOGICAL CHEMISTRY*, vol. 271, no. 23, 7 June 1996, pages 13875-13881, XP002058248 cited in the application
- **HIRAYAMA T ET AL.:** "CLONING AND CHARACTERIZATION OF SEVEN CDNAS FOR HYPEROSMOLARITY- RESPONSIVE (HOR) GENES OF *SACCHAROMYCES CEREVISIAE*" *MOLECULAR AND GENERAL GENETICS*, vol. 249, 1995, pages 127-138, XP002058249 cited in the application

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

- LARSSON K. ET AL.: "A gene encoding sn-glycerol 3-phosphate dehydrogenase (NAD⁺) complements an osmosensitive mutant of *Saccharomyces cerevisiae*." MOLECULAR MICROBIOLOGY, vol. 10, no. 5, 1993, pages 1101-1111, XP000562759 cited in the application
- OMORI T. ET AL.: "Breeding of high glycerol-producing shochu yeast (*Saccharomyces cerevisiae*) with acquired salt tolerance." JOURNAL OF FERMENTATION AND BIOENGINEERING, vol. 79, no. 6, 1995, pages 560-565, XP002058250

Description**FIELD OF INVENTION**

5 [0001] The present invention relates to the field of molecular biology and the use of recombinant organisms for the production of glycerol and compounds derived from the glycerol biosynthetic pathway. More specifically the invention describes the construction of a recombinant cell for the production of glycerol and derived compounds from a carbon substrate, the cell containing foreign genes encoding proteins having glycerol-3-phosphate dehydrogenase (G3PDH) and glycerol-3-phosphatase (G3P phosphatase) activities where the endogenous genes encoding the glycerol-converting glycerol kinase and glycerol dehydrogenase activities have been deleted.

BACKGROUND

15 [0002] Glycerol is a compound in great demand by industry for use in cosmetics, liquid soaps, food, pharmaceuticals, lubricants, anti-freeze solutions, and in numerous other applications. The esters of glycerol are important in the fat and oil industry. Historically, glycerol has been isolated from animal fat and similar sources; however, the process is laborious and inefficient. Microbial production of glycerol is preferred.

20 [0003] Not all organisms have a natural capacity to synthesize glycerol. However, the biological production of glycerol is known for some species of bacteria, algae, and yeast. The bacteria *Bacillus licheniformis* and *Lactobacillus lycopersica* synthesize glycerol. Glycerol production is found in the halotolerant algae *Dunaliella* sp. and *Asteromonas gracilis* for protection against high external salt concentrations (Ben-Amotz et al., (1982) *Experientia* 38:49-52). Similarly, various osmotolerant yeast synthesize glycerol as a protective measure. Most strains of *Saccharomyces* produce some glycerol during alcoholic fermentation and this production can be increased by the application of osmotic stress (Albertyn et al., (1994) *Mol. Cell. Biol.* 14, 4135-4144). Earlier this century glycerol was produced commercially with *Saccharomyces* cultures to which steering reagents were added such as sulfites or alkalis. Through the formation of an inactive complex, the steering agents block or inhibit the conversion of acetaldehyde to ethanol; thus, excess reducing equivalents (NADH) are available to or "steered" towards dihydroxyacetone phosphate (DHAP) for reduction to produce glycerol. This method is limited by the partial inhibition of yeast growth that is due to the sulfites. This limitation can be partially overcome by the use of alkalis which create excess NADH equivalents by a different mechanism. In this practice, the alkalis initiated a Cannizarro disproportionation to yield ethanol and acetic acid from two equivalents of acetaldehyde. Thus, although production of glycerol is possible from naturally occurring organisms, production is often subject to the need to control osmotic stress of the cultures and the production of sulfites. A method free from these limitations is desirable. Production of glycerol from recombinant organisms containing foreign genes encoding key steps in the glycerol biosynthetic pathway is one possible route to such a method.

30 [0004] A number of the genes involved in the glycerol biosynthetic pathway have been isolated. For example, the gene encoding glycerol-3-phosphate dehydrogenase (DAR1, GPD1) has been cloned and sequenced from *Saccharomyces diastaticus* (Wang et al., (1994), *J. Bact.* 176:7091-7095). The DAR1 gene was cloned into a shuttle vector and used to transform *E. coli* where expression produced active enzyme. Wang et al., *supra*, recognizes that DAR1 is regulated by the cellular osmotic environment but does not suggest how the gene might be used to enhance glycerol production in a recombinant organism.

40 [0005] Other glycerol-3-phosphate dehydrogenase enzymes have been isolated. For example, sn-glycerol-3-phosphate dehydrogenase has been cloned and sequenced from *S. cerevisiae* (Larason et al., (1993) *Mol. Microbiol.*, 10: 1101). Albertyn et al., (1994) *Mol. Cell. Biol.*, 14:4135) teach the cloning of GPD1 encoding a glycerol-3-phosphate dehydrogenase from *S. cerevisiae*. Like Wang et al., both Albertyn et al. and Larason et al. recognize the osmo-sensitivity of the regulation of this gene but do not suggest how the gene might be used in the production of glycerol in a recombinant organism.

45 [0006] As with G3PDH, glycerol-3-phosphatase has been isolated from *Saccharomyces cerevisiae* and the protein identified as being encoded by the GPP1 and GPP2 genes (Norbeck et al., (1996) *J. Biol. Chem.*, 271:13875). Like the genes encoding G3PDH, it appears that GPP2 is osmotically-induced.

50 [0007] Although the genes encoding G3PDH and G3P phosphatase have been isolated, there is no teaching in the art that demonstrates glycerol production from recombinant organisms with G3PDH/G3P phosphatase expressed together or separately. Further, there is no teaching to suggest that efficient glycerol production from any wild-type organism is possible using these two enzyme activities that does not require applying some stress (salt or an osmolyte) to the cell. In fact, the art suggests that G3PDH activities may not affect glycerol production. For example, Eustace ((1987), *Can. J. Microbiol.*, 33:112-117)) teaches hybridized yeast strains that produced glycerol at greater levels than the parent strains. However, Eustace also demonstrates that G3PDH activity remained constant or slightly lower in the hybridized strains as opposed to the wild type.

55 [0008] Glycerol is an industrially useful material. However, other compounds may be derived from the glycerol bio-

synthetic pathway that also have commercial significance. For example, glycerol-producing organisms may be engineered to produce 1,3-propanediol (U.S. 5686276), a monomer having potential utility in the production of polyester fibers and the manufacture of polyurethanes and cyclic compounds. It is known for example that in some organisms, glycerol is converted to 3-hydroxypropionaldehyde and then to 1,3-propanediol through the actions of a dehydratase enzyme and an oxidoreductase enzyme, respectively. Bacterial strains able to produce 1,3-propanediol have been found, for example, in the groups *Citrobacter*, *Clostridium*, *Enterobacter*, *Illyobacter*, *Klebsiella*, *Lactobacillus*, and *Pelobacter*. Glycerol dehydratase and diol dehydratase systems are described by Seyfried et al. (1996) *J. Bacteriol.* 178: 5793-5796 and Tobimatsu et al. (1995) *J. Biol. Chem.* 270:7142-7148, respectively. Recombinant organisms, containing exogenous dehydratase enzyme, that are able to produce 1,3-propanediol have been described (U.S. 5686276). Although these organisms produce 1,3-propanediol, it is clear that they would benefit from a system that would minimize glycerol conversion.

[0009] There are a number of advantages in engineering a glycerol-producing organism for the production of 1,3-propanediol where conversion of glycerol is minimized. A microorganism capable of efficiently producing glycerol under physiological conditions is industrially desirable, especially when the glycerol itself will be used as a substrate *in vivo* as part of a more complex catabolic or biosynthetic pathway that could be perturbed by osmotic stress or the addition of steering agents (e.g., the production of 1,3-propanediol). Some attempts at creating glycerol kinase and glycerol dehydrogenase mutants have been made. For example, De Koning et al. (1990) *Appl. Microbiol Biotechnol.* 32:693-698 report the methanol-dependent production of dihydroxyacetone and glycerol by mutants of the methylotrophic yeast *Hansenula polymorpha* blocked in dihydroxyacetone kinase and glycerol kinase. Methanol and an additional substrate, required to replenish the xylose-5-phosphate co-substrate of the assimilation reaction, were used to produce glycerol; however, a dihydroxyacetone reductase (glycerol dehydrogenase) is also required. Similarly, Shaw and Cameron, Book of Abstracts, 211th ACS National Meeting, New Orleans, LA, March 24-28 (1996), BIOT-154 Publisher: American Chemical Society, Washington, D. C., investigate the deletion of *ldhA* (lactate dehydrogenase), *glpK* (glycerol kinase), and *tpiA* (triosephosphate isomerase) for the optimization of 1,3-propanediol production. They do not suggest the expression of cloned genes for G3PDH or G3P phosphatase for the production of glycerol or 1,3-propanediol and they do not discuss the impact of glycerol dehydrogenase.

[0010] The problem to be solved, therefore, is the lack of a process to direct carbon flux towards glycerol production by the addition or enhancement of certain enzyme activities, especially G3PDH and G3P phosphatase which respectively catalyze the conversion of dihydroxyacetone phosphate (DHAP) to glycerol-3-phosphate (G3P) and then to glycerol. The problem is complicated by the need to control the carbon flux away from glycerol by deletion or decrease of certain enzyme activities, especially glycerol kinase and glycerol dehydrogenase which respectively catalyze the conversion of glycerol plus ATP to G3P and glycerol to dihydroxyacetone (or glyceraldehyde).

SUMMARY OF THE INVENTION

[0011] The present invention provides a method for the production of glycerol from a recombinant organism comprising: transforming a suitable host cell with an expression cassette comprising (a) a gene encoding a protein having glycerol-3-phosphate dehydrogenase activity and (b) a gene encoding a protein having glycerol-3-phosphate phosphatase activity, where the suitable host cell contains a disruption in (a) an endogenous gene encoding a polypeptide having glycerol kinase activity and (b) optionally an endogenous gene encoding a polypeptide having glycerol dehydrogenase activity, wherein the disruption prevents the expression of active gene product; culturing the transformed host cell in the presence of at least one carbon source selected from the group consisting of monosaccharides, oligosaccharides, polysaccharides, and single-carbon substrates, whereby glycerol is produced; and recovering the glycerol produced.

[0012] The present invention further provides a process for the production of 1,3-propanediol from a recombinant organism comprising: transforming a suitable host cell with an expression cassette comprising (a) a gene encoding a protein having glycerol-3-phosphate dehydrogenase activity and (b) a gene encoding a protein having glycerol-3-phosphate phosphatase activity, the suitable host cell having at least one gene encoding a protein having a dehydratase activity and having a disruption in (a) an endogenous gene encoding a polypeptide having glycerol kinase activity and (b) optionally an endogenous gene encoding a polypeptide having glycerol dehydrogenase activity, wherein the disruption in the genes of (a) and optionally (b) prevents the expression of active gene product; culturing the transformed host cell in the presence of at least one carbon source selected from the group consisting of monosaccharides, oligosaccharides, polysaccharides, and single-carbon substrates whereby 1,3-propanediol is produced; and recovering the 1,3-propanediol produced.

[0013] Additionally, the invention provides for a process for the production of 1,3-propanediol from a recombinant organism where multiple copies of endogenous genes are introduced.

[0014] Further embodiments of the invention include host cells transformed with heterologous genes for the glycerol pathway as well as host cells which contain endogenous genes for the glycerol pathway.

5 [0015] Additionally, the invention provides recombinant cells suitable for the production either glycerol or 1,3-propanediol, the host cells having genes expressing either one or both of a glycerol-3-phosphate dehydrogenase activity and a glycerol-3-phosphate phosphatase activity wherein the cell also has disruptions in either one or both of a gene encoding an endogenous glycerol kinase and a gene encoding an endogenous glycerol dehydrogenase, wherein the disruption in the genes prevents the expression of active gene product.

BRIEF DESCRIPTION OF THE BIOLOGICAL DEPOSITS AND SEQUENCE LISTING

10 [0016] Applicants have made the following biological deposits under the terms of the Budapest Treaty on the International Recognition of the Deposit of Micro-organisms for the Purposes of Patent Procedure:

Depositor Identification Reference	Int'l. Depository Designation	Date of Deposit
<i>Escherichia coli</i> pAH21/DH5 α (containing the GPP2 gene)	ATCC 98187	26 September 1996
<i>Escherichia coli</i> (pDAR1A/AA200) (containing the DAR1 gene)	ATCC 98248	6 November 1996
<i>FM5 Escherichia coli</i> RJJF10m (containing a <i>glpk</i> disruption)	ATCC 98597	25 November 1997
<i>FM5 Escherichia coli</i> MSP33.6 (containing a <i>gldA</i> disruption)	ATCC 98598	25 November 1997

"ATCC" refers to the American Type Culture Collection international depository located at 12301 Parklawn Drive, Rockville, MD 20852 U.S.A. The designation is the accession number of the deposited material.

25 [0017] Applicants have provided 43 sequences in conformity with the Rules for the Standard Representation of Nucleotide and Amino Acid Sequences in Patent Applications (Annexes I and II to the Decision of the President of the EPO, published in Supplement No. 2 to OJ EPO, 12/1992) and with 37 C.F.R. 1.821-1.825 and Appendices A and B (Requirements for Application Disclosures Containing Nucleotides and/or Amino Acid Sequences).

DETAILED DESCRIPTION OF THE INVENTION

30 [0018] The present invention solves the problem stated above by providing a method for the biological production of glycerol from a fermentable carbon source in a recombinant organism. The method provides a rapid, inexpensive and environmentally-responsible source of glycerol useful in the cosmetics and pharmaceutical industries. The method uses a microorganism containing cloned homologous or heterologous genes encoding glycerol-3-phosphate dehydrogenase (G3PDH) and/or glycerol-3-phosphatase (G3P phosphatase). These genes are expressed in a recombinant host having disruptions in genes encoding endogenous glycerol kinase and optionally glycerol dehydrogenase enzymes. The method is useful for the production of glycerol, as well as any end products for which glycerol is an intermediate. The recombinant microorganism is contacted with a carbon source and cultured and then glycerol or any end products derived therefrom are isolated from the conditioned media. The genes may be incorporated into the host microorganism separately or together for the production of glycerol.

35 [0019] Applicants' process has not previously been described for a recombinant organism and required the isolation of genes encoding the two enzymes and their subsequent expression in a host cell having disruptions in the endogenous kinase and dehydrogenase genes. It will be appreciated by those familiar with this art that Applicants' process may be generally applied to the production compounds where glycerol is a key intermediate, e.g., 1,3-propanediol.

40 [0020] As used herein the following terms may be used for interpretation of the claims and specification.

45 [0021] The terms "glycerol-3-phosphate dehydrogenase" and "G3PDH" refer to a polypeptide responsible for an enzyme activity that catalyzes the conversion of dihydroxyacetone phosphate (DHAP) to glycerol-3-phosphate (G3P). *In vivo* G3PDH may be NADH; NADPH; or FAD-dependent. The NADH-dependent enzyme (EC 1.1.1.8) is encoded, for example, by several genes including GPD 1 (GenBank Z74071x2), or GPD2 (GenBank Z35169x1), or GPD3 (GenBank G984182), or DAR1 (GenBank Z74071x2). The NADPH-dependent enzyme (EC 1.1.1.94) is encoded by *gpsA* (GenBank U321643, (cds 197911-196892) G466746 and L45246). The FAD-dependent enzyme (EC 1.1.99.5) is encoded by GUT2 (GenBank 247047x23), or *glpD* (GenBank G147838), or *glpABC* (GenBank M20938).

50 [0022] The terms "glycerol-3-phosphatase", "sn-glycerol-3-phosphatase", or "d,1-glycerol phosphatase", and "G3P phosphatase" refer to a polypeptide responsible for an enzyme activity that catalyzes the conversion of glycerol-3-phosphate and water to glycerol and inorganic phosphate. G3P phosphatase is encoded, for example, by GPP1 (GenBank Z47047x125), or GPP2 (GenBank U18813x11).

[0023] The term "glycerol kinase" refers to a polypeptide responsible for an enzyme activity that catalyzes the conversion of glycerol and ATP to glycerol-3-phosphate and ADP. The high energy phosphate donor ATP may be replaced by physiological substitutes (e.g. phosphoenolpyruvate). Glycerol kinase is encoded, for example, by GUT1 (GenBank U11583x19) and *glpK* (GenBank L19201).

5 [0024] The term "glycerol dehydrogenase" refers to a polypeptide responsible for an enzyme activity that catalyzes the conversion of glycerol to dihydroxyacetone (E.C. 1.1.1.6) or glycerol to glyceraldehyde (E.C. 1.1.1.72). A polypeptide responsible for an enzyme activity that catalyzes the conversion of glycerol to dihydroxyacetone is also referred to as a "dihydroxyacetone reductase". Glycerol dehydrogenase may be dependent upon NADH (E.C. 1.1.1.6), NADPH (E.C. 1.1.1.72), or other cofactors (e.g., E.C. 1.1.99.22). A NADH-dependent glycerol dehydrogenase is encoded, for example, by *gldA* (GenBank U00006).

10 [0025] The term "dehydratase enzyme" will refer to any enzyme that is capable of isomerizing or converting a glycerol molecule to the product 3-hydroxypropion-aldehyde. For the purposes of the present invention the dehydratase enzymes include a glycerol dehydratase (E.C. 4.2.1.30) and a diol dehydratase (E.C. 4.2.1.28) having preferred substrates of glycerol and 1,2-propanediol, respectively. In *Citrobacter freundii*, for example, glycerol dehydratase is encoded by three polypeptides whose gene sequences are represented by *dhaB*, *dhaC* and *dhaE* (GenBank U09771: base pairs 8556-10223, 10235-10819, and 10822-11250, respectively). In *Klebsiella oxytoca*, for example, diol dehydratase is encoded by three polypeptides whose gene sequences are represented by *pddA*, *pddB*, and *pddC* (GenBank D45071: base pairs 121-1785, 1796-2470, and 2485-3006, respectively).

15 [0026] The terms "GPD1", "DAR1", "OSG1", "D2830", and "YDL022W" will be used interchangeably and refer to a gene that encodes a cytosolic glycerol-3-phosphate dehydrogenase and is characterized by the base sequence given as SEQ ID NO:1.

20 [0027] The term "GPD2" refers to a gene that encodes a cytosolic glycerol-3-phosphate dehydrogenase and is characterized by the base sequence given in SEQ ID NO:2.

25 [0028] The terms "GUT2" and "YIL155C" are used interchangeably and refer to a gene that encodes a mitochondrial glycerol-3-phosphate dehydrogenase and is characterized by the base sequence given in SEQ ID NO:3.

[0029] The terms "GPP1", "RHR2" and "YIL053W" are used interchangeably and refer to a gene that encodes a cytosolic glycerol-3-phosphatase and is characterized by the base sequence given in SEQ ID NO:4.

[0030] The terms "GPP2", "HOR2" and "YER062C" are used interchangeably and refer to a gene that encodes a cytosolic glycerol-3-phosphatase and is characterized by the base sequence given as SEQ ID NO:5.

30 [0031] The term "GUT1" refers to a gene that encodes a cytosolic glycerol kinase and is characterized by the base sequence given as SEQ ID NO:6. The term "*glpK*" refers to another gene that encodes a glycerol kinase and is characterized by the base sequence given in GeneBank L19201, base pairs 77347-78855.

35 [0032] The term "*gldA*" refers to a gene that encodes a glycerol dehydrogenase and is characterized by the base sequence given in GeneBank U00006, base pairs 3174-4316. The term "*dhaD*" refers to another gene that encodes a glycerol dehydrogenase and is characterized by the base sequence given in GeneBank U09771, base pairs 2557-3654.

[0033] As used herein, the terms "function" and "enzyme function" refer to the catalytic activity of an enzyme in altering the energy required to perform a specific chemical reaction. Such an activity may apply to a reaction in equilibrium where the production of both product and substrate may be accomplished under suitable conditions.

40 [0034] The terms "polypeptide" and "protein" are used interchangeably.

[0035] The terms "carbon substrate" and "carbon source" refer to a carbon source capable of being metabolized by host organisms of the present invention and particularly mean carbon sources selected from the group consisting of monosaccharides, oligosaccharides, polysaccharides, and one-carbon substrates or mixtures thereof.

45 [0036] "Conversion" refers to the metabolic processes of an organism or cell that by means of a chemical reaction degrades or alters the complexity of a chemical compound or substrate.

[0037] The terms "host cell" and "host organism" refer to a microorganism capable of receiving foreign or heterologous genes and additional copies of endogeneous genes and expressing those genes to produce an active gene product.

50 [0038] The terms "production cell" and "production organism" refer to a cell engineered for the production of glycerol or compounds that may be derived from the glycerol biosynthetic pathway. The production cell will be recombinant and contain either one or both of a gene that encodes a protein having a glycerol-3-phosphate dehydrogenase activity and a gene encoding a protein having a glycerol-3-phosphatase activity. In addition to the G3PDH and G3P phosphatase genes, the host cell will contain disruptions in one or both of a gene encoding an endogenous glycerol kinase and a gene encoding an endogenous glycerol dehydrogenase. Where the production cell is designed to produce 1,3-propanediol, it will additionally contain a gene encoding a protein having a dehydratase activity.

55 [0039] The terms "foreign gene", "foreign DNA", "heterologous gene", and "heterologous DNA" all refer to genetic material native to one organism that has been placed within a different host organism.

[0040] The term "endogenous" as used herein with reference to genes or polypeptides expressed by genes, refers

to genes or polypeptides that are native to a production cell and are not derived from another organism. Thus an "endogenous glycerol kinase" and an "endogenous glycerol dehydrogenase" are terms referring to polypeptides encoded by genes native to the production cell.

[0041] The terms "recombinant organism" and "transformed host" refer to any organism transformed with heterologous or foreign genes. The recombinant organisms of the present invention express foreign genes encoding G3PDH and G3P phosphatase for the production of glycerol from suitable carbon substrates. Additionally, the terms "recombinant organism" and "transformed host" refer to any organism transformed with endogenous (or homologous) genes so as to increase the copy number of the genes.

[0042] "Gene" refers to a nucleic acid fragment that expresses a specific protein, including regulatory sequences preceding (5' non-coding) and following (3' non-coding) the coding region. The terms "native" and "wild-type" gene refer to the gene as found in nature with its own regulatory sequences.

[0043] The terms "encoding" and "coding" refer to the process by which a gene, through the mechanisms of transcription and translation, produces an amino acid sequence. The process of encoding a specific amino acid sequence is meant to include DNA sequences that may involve base changes that do not cause a change in the encoded amino acid, or which involve base changes which may alter one or more amino acids, but do not affect the functional properties of the protein encoded by the DNA sequence. Therefore, the invention encompasses more than the specific exemplary sequences. Modifications to the sequence, such as deletions, insertions, or substitutions in the sequence which produce silent changes that do not substantially affect the functional properties of the resulting protein molecule are also contemplated. For example, alterations in the gene sequence which reflect the degeneracy of the genetic code, or which result in the production of a chemically equivalent amino acid at a given site, are contemplated; thus, a codon for the amino acid alanine, a hydrophobic amino acid, may be substituted by a codon encoding another less hydrophobic residue, such as glycine, or a more hydrophobic residue, such as valine, leucine, or isoleucine. Similarly, changes which result in substitution of one negatively charged residue for another, such as aspartic acid for glutamic acid, or one positively charged residue for another, such as lysine for arginine, can also be expected to produce a biologically equivalent product. Nucleotide changes which result in alteration of the N-terminal and C-terminal portions of the protein molecule would also not be expected to alter the activity of the protein. In some cases, it may in fact be desirable to make mutants of the sequence in order to study the effect of alteration on the biological activity of the protein. Each of the proposed modifications is well within the routine skill in the art, as is determination of retention of biological activity in the encoded products. Moreover, the skilled artisan recognizes that sequences encompassed by this invention are also defined by their ability to hybridize, under stringent conditions (0.1X SSC, 0.1 % SDS, 65 °C), with the sequences exemplified herein.

[0044] The term "expression" refers to the transcription and translation to gene product from a gene coding for the sequence of the gene product.

[0045] The terms "plasmid", "vector", and "cassette" as used herein refer to an extra chromosomal element often carrying genes which are not part of the central metabolism of the cell and usually in the form of circular double-stranded DNA molecules. Such elements may be autonomously replicating sequences, genome integrating sequences, phage or nucleotide sequences, linear or circular, of a single- or double-stranded DNA or RNA, derived from any source, in which a number of nucleotide sequences have been joined or recombined into a unique construction which is capable of introducing a promoter fragment and DNA sequence for a selected gene product along with appropriate 3' untranslated sequence into a cell. "Transformation cassette" refers to a specific vector containing a foreign gene and having elements in addition to the foreign gene that facilitate transformation of a particular host cell. "Expression cassette" refers to a specific vector containing a foreign gene and having elements in addition to the foreign gene that allow for enhanced expression of that gene in a foreign host.

[0046] The terms "transformation" and "transfection" refer to the acquisition of new genes in a cell after the incorporation of nucleic acid. The acquired genes may be integrated into chromosomal DNA or introduced as extrachromosomal replicating sequences. The term "transformant" refers to the cell resulting from a transformation.

[0047] The term "genetically altered" refers to the process of changing hereditary material by transformation or mutation. The terms "disruption" and "gene interrupt" as applied to genes refer to a method of genetically altering an organism by adding to or deleting from a gene a significant portion of that gene such that the protein encoded by that gene is either not expressed or not expressed in active form.

Glycerol Biosynthetic Pathway

[0048] It is contemplated that glycerol may be produced in recombinant organisms by the manipulation of the glycerol biosynthetic pathway found in most microorganisms. Typically, a carbon substrate such as glucose is converted to glucose-6-phosphate via hexokinase in the presence of ATP. Glucose-phosphate isomerase catalyzes the conversion of glucose-6-phosphate to fructose-6-phosphate and then to fructose-1,6-diphosphate through the action of 6-phosphofructokinase. The diphosphate is then taken to dihydroxyacetone phosphate (DHAP) via aldolase. Finally NADH-

dependent G3PDH converts DHAP to glycerol-3-phosphate which is then dephosphorylated to glycerol by G3P phosphatase. (Agarwal (1990), *Adv. Biochem. Engrg.* 41:114).

5 Genes encoding G3PDH, glycerol dehydrogenase, G3P phosphatase and glycerol kinase

[0049] The present invention provides genes suitable for the expression of G3PDH and G3P phosphatase activities in a host cell.

[0050] Genes encoding G3PDH are known. For example, GPD1 has been isolated from *Saccharomyces* and has the base sequence given by SEQ ID NO:1, encoding the amino acid sequence given in SEQ ID NO:7 (Wang et al., *supra*). Similarly, G3PDH activity has also been isolated from *Saccharomyces* encoded by GPD2 having the base sequence given in SEQ ID NO:2 encoding the amino acid sequence given in SEQ ID NO:8 (Eriksson et al., (1995) *Mol. Microbiol.*, 17:95).

[0051] For the purposes of the present invention it is contemplated that any gene encoding a polypeptide responsible for G3PDH activity is suitable wherein that activity is capable of catalyzing the conversion of dihydroxyacetone phosphate (DHAP) to glycerol-3-phosphate (G3P). Further, it is contemplated that any gene encoding the amino acid sequence of G3PDH as given by SEQ ID NOS:7, 8, 9, 10, 11 and 12 corresponding to the genes GPD1, GPD2, GUT2, gpsA, glpD, and the α subunit of glpABC respectively, will be functional in the present invention wherein that amino acid sequence may encompass amino acid substitutions, deletions or additions that do not alter the function of the enzyme. The skilled person will appreciate that genes encoding G3PDH isolated from other sources will also be suitable for use in the present invention. For example, genes isolated from prokaryotes include GenBank accessions M34393, M20938, L06231, U12567, L45246, L45323, L45324, L45325, U32164, U32689, and U39682. Genes isolated from fungi include GenBank accessions U30625, U30876 and X56162; genes isolated from insects include GenBank accessions X61223 and X14179; and genes isolated from mammalian sources include GenBank accessions U 12424, M25558 and X78593.

[0052] Genes encoding G3P phosphatase are known. For example, GPP2 has been isolated from *Saccharomyces cerevisiae* and has the base sequence given by SEQ ID NO:5, which encodes the amino acid sequence given in SEQ ID NO:13 (Norbeck et al., (1996), *J. Biol. Chem.*, 271:13875).

[0053] For the purposes of the present invention, any gene encoding a G3P phosphatase activity is suitable for use in the method wherein that activity is capable of catalyzing the conversion of glycerol-3-phosphate and water to glycerol and inorganic phosphate. Further, any gene encoding the amino acid sequence of G3P phosphatase as given by SEQ ID NOS:13 and 14 corresponding to the genes GPP2 and GPP1 respectively, will be functional in the present invention including any amino acid sequence that encompasses amino acid substitutions, deletions or additions that do not alter the function of the G3P phosphatase enzyme. The skilled person will appreciate that genes encoding G3P phosphatase isolated from other sources will also be suitable for use in the present invention. For example, the dephosphorylation of glycerol-3-phosphate to yield glycerol may be achieved with one or more of the following general or specific phosphatases: alkaline phosphatase (EC 3.1.3.1) [GenBank M19159, M29663, U02550 or M33965]; acid phosphatase (EC 3.1.3.2) [GenBank U51210, U19789, U28658 or L20566]; glycerol-3-phosphatase (EC 3.1.3.-) [GenBank Z38060 or U18813x11]; glucose-1-phosphatase (EC 3.1.3.10) [GenBank M33807]; glucose-6-phosphatase (EC 3.1.3.9) [GenBank U00445]; fructose-1,6-bisphosphatase (EC 3.1.3.11) [GenBank X12545 or J03207] or phosphotidyl glycerophosphate phosphatase (EC 3.1.3.27) [GenBank M23546 and M23628].

[0054] Genes encoding glycerol kinase are known. For example, GUT1 encoding the glycerol kinase from *Saccharomyces* has been isolated and sequenced (Pavlik et al. (1993), *Curr. Genet.*, 24:21) and the base sequence is given by SEQ ID NO:6, which encodes the amino acid sequence given in SEQ ID NO: 15. Alternatively, *glpK* encodes a glycerol kinase from *E. coli* and is characterized by the base sequence given in GeneBank L19201, base pairs 77347-78855.

[0055] Genes encoding glycerol dehydrogenase are known. For example, *gldA* encodes a glycerol dehydrogenase from *E. coli* and is characterized by the base sequence given in GeneBank U00006, base pairs 3174-4316. Alternatively, *dhaD* refers to another gene that encodes a glycerol dehydrogenase from *Citrobacter freundii* and is characterized by the base sequence given in GeneBank U09771, base pairs 2557-3654.

50 Host cells

[0056] Suitable host cells for the recombinant production of glycerol by the expression of G3PDH and G3P phosphatase may be either prokaryotic or eukaryotic and will be limited only by their ability to express active enzymes. Preferred host cells will be those bacteria, yeasts, and filamentous fungi typically useful for the production of glycerol such as *Citrobacter*, *Enterobacter*, *Clostridium*, *Klebsiella*, *Aerobacter*, *Lactobacillus*, *Aspergillus*, *Saccharomyces*, *Schizosaccharomyces*, *Zygosaccharomyces*, *Pichia*, *Kluyveromyces*, *Candida*, *Hansenula*, *Debaromyces*, *Mucor*, *Torulopsis*, *Methylobacter*, *Escherichia*, *Salmonella*, *Bacillus*, *Streptomyces* and *Pseudomonas*. Preferred in the

present invention are *E. coli* and *Saccharomyces*.

[0057] Where glycerol is a key intermediate in the production of 1,3-propanediol the host cell will either have an endogenous gene encoding a protein having a dehydratase activity or will acquire such a gene through transformation. Host cells particularly suited for production of 1,3-propanediol are *Citrobacter*, *Enterobacter*, *Clostridium*, *Klebsiella*, *Aerobacter*, *Lactobacillus*, and *Salmonella*, which have endogenous genes encoding dehydratase enzymes. Additionally, host cells that lack such an endogenous gene include *E. coli*.

Vectors And Expression Cassettes

[0058] The present invention provides a variety of vectors and transformation and expression cassettes suitable for the cloning, transformation and expression of G3PDH and G3P phosphatase into a suitable host cell. Suitable vectors will be those which are compatible with the bacterium employed. Suitable vectors can be derived, for example, from a bacteria, a virus (such as bacteriophage T7 or a M-13 derived phage), a cosmid, a yeast or a plant. Protocols for obtaining and using such vectors are known to those in the art (Sambrook et al., Molecular Cloning: A Laboratory Manual - volumes 1, 2, 3 (Cold Spring Harbor Laboratory: Cold Spring Harbor, NY, 1989)).

[0059] Typically, the vector or cassette contains sequences directing transcription and translation of the appropriate gene, a selectable marker, and sequences allowing autonomous replication or chromosomal integration. Suitable vectors comprise a region 5' of the gene which harbors transcriptional initiation controls and a region 3' of the DNA fragment which controls transcriptional termination. It is most preferred when both control regions are derived from genes homologous to the transformed host cell. Such control regions need not be derived from the genes native to the specific species chosen as a production host.

[0060] Initiation control regions, or promoters, which are useful to drive expression of the G3PDH and G3P phosphatase genes in the desired host cell are numerous and familiar to those skilled in the art. Virtually any promoter capable of driving these genes is suitable for the present invention including but not limited to CYC1, HIS3, GAL1, GAL10, ADH1, PGK, PHO5, GAPDH, ADC1, TRP1, URA3, LEU2, ENO, and TPI (useful for expression in *Saccharomyces*); AOX1 (useful for expression in *Pichia*); and lac, trp, λP_L, λP_R, T7, tac, and trc, (useful for expression in *E. coli*).

[0061] Termination control regions may also be derived from various genes native to the preferred hosts. Optionally, a termination site may be unnecessary; however, it is most preferred if included.

[0062] For effective expression of the instant enzymes, DNA encoding the enzymes are linked operably through initiation codons to selected expression control regions such that expression results in the formation of the appropriate messenger RNA.

Transformation Of Suitable Hosts And Expression Of G3PDH And G3P Phosphatase For The Production Of Glycerol

[0063] Once suitable cassettes are constructed they are used to transform appropriate host cells. Introduction of the cassette containing the genes encoding G3PDH and/or G3P phosphatase into the host cell may be accomplished by known procedures such as by transformation, e.g., using calcium-permeabilized cells, electroporation, or by transfection using a recombinant phage virus (Sambrook et al., *supra*).

[0064] In the present invention AH21 and DAR1 cassettes were used to transform the *E. coli* DH5 α and FM5 as fully described in the GENERAL METHODS and EXAMPLES.

[0065] Alternatively, it is contemplated that suitable host cells comprising endogenous G3PDH and/or G3P phosphatase genes may be manipulated so that the relevant genes are upregulated for the production of glycerol.

[0066] Methods for upregulation of endogenous genes are well known in the art. For example, to upregulate the desired gene(s), a structural gene is generally placed downstream from a promoter region on the DNA which is recognized by the recipient microorganism. In addition to the promoter, one may include other regulatory sequences that increase or control expression from heterologous genes. In addition, one may alter the regulatory sequences of endogenous genes by any known genetic manipulation for the same purpose. Expression may be controlled by an inducer or a repressor so that the microorganism coordinately expresses the gene(s) necessary to complete the desired metabolic pathway.

[0067] In the instant invention host cells containing endogenous genes encoding G3PDH and/or G3P phosphatase activities could be placed under the control of regulated promoters (e.g. lac or osmy) or constitutive promoters. For example, a cassette may be constructed to contain a specific inducible or constitutive promoter, flanked by DNA of sufficient length and homology to the native gene to permit targeting. Introduction of the cassette under suitable growth conditions will result in homologous recombination between the cassette and the targeted portion of the gene and the replacement of the relevant native promoter with the regulatable promoter. Such methods may be employed to effect the upregulation of endogenous genes encoding G3PDH and/or G3P phosphatase activities for the production of glycerol.

Random And Site Specific Mutagenesis For Disrupting Enzyme Activities:

[0068] Enzyme pathways by which organisms metabolize glycerol are known in the art. Glycerol is converted to glycerol-3-phosphate (G3P) by an ATP-dependent glycerol kinase; the G3P may then be oxidized to DHAP by G3PDH. In a second pathway, glycerol is oxidized to dihydroxyacetone (DHA) by a glycerol dehydrogenase; the DHA may then be converted to DHAP by an ATP-dependent DHA kinase. In a third pathway, glycerol is oxidized to glyceraldehyde by a glycerol dehydrogenase; the glyceraldehyde may be phosphorylated to glyceraldehyde-3-phosphate by an ATP-dependent kinase. DHAP and glyceraldehyde-3-phosphate, interconverted by the action of triosephosphate isomerase, may be further metabolized via central metabolism pathways. These pathways, by introducing by-products, are deleterious to glycerol production.

[0069] One aspect of the present invention is the ability to provide a production organism for the production of glycerol where the glycerol-converting activities of glycerol kinase and glycerol dehydrogenase have been deleted. Methods of creating deletion mutants are common and well known in the art. For example, wild type cells may be exposed to a variety of agents such as radiation or chemical mutagens and then screened for the desired phenotype. When creating mutations through radiation either ultraviolet (UV) or ionizing radiation may be used. Suitable short wave UV wavelengths for genetic mutations will fall within the range of 200 nm to 300 nm where 254 nm is preferred. UV radiation in this wavelength principally causes changes within nucleic acid sequence from guanine and cytosine to adenine and thymidine. Since all cells have DNA repair mechanisms that would repair most UV induced mutations, agents such as caffeine and other inhibitors may be added to interrupt the repair process and maximize the number of effective mutations. Long wave UV mutations using light in the 300 nm to 400 nm range are also possible but are generally not as effective as the short wave UV light unless used in conjunction with various activators such as psoralen dyes that interact with the DNA.

[0070] Mutagenesis with chemical agents is also effective for generating mutants and commonly used substances include chemicals that affect nonreplicating DNA such as HNO_2 and NH_2OH , as well as agents that affect replicating DNA such as acridine dyes, notable for causing frameshift mutations. Specific methods for creating mutants using radiation or chemical agents are well documented in the art. See for example Thomas D. Brock in *Biotechnology: A Textbook of Industrial Microbiology*, Second Edition (1989) Sinauer Associates, Inc., Sunderland, MA., or Deshpande, Mukund V., *Appl. Biochem. Biotechnol.*, 36, 227, (1992), herein incorporated by reference.

[0071] After mutagenesis has occurred, mutants having the desired phenotype may be selected by a variety of methods. Random screening is most common where the mutagenized cells are selected for the ability to produce the desired product or intermediate. Alternatively, selective isolation of mutants can be performed by growing a mutagenized population on selective media where only resistant colonies can develop. Methods of mutant selection are highly developed and well known in the art of industrial microbiology. See Brock, *Supra.*, DeMancilha et al., *Food Chem.*, 14, 313, (1984).

[0072] Biological mutagenic agents which target genes randomly are well known in the art. See for example De Bruijn and Rossbach in *Methods for General and Molecular Bacteriology* (1994) American Society for Microbiology, Washington, D.C. Alternatively, provided that gene sequence is known, chromosomal gene disruption with specific deletion or replacement is achieved by homologous recombination with an appropriate plasmid. See for example Hamilton et al. (1989) *J. Bacteriol.* 171:4617-4622, Balbas et al. (1993) *Gene* 136:211-213, Gueldener et al. (1996) *Nucleic Acids Res.* 24:2519-2524, and Smith et al. (1996) *Methods Mol. Cell. Biol.* 5:270-277.

[0073] It is contemplated that any of the above cited methods may be used for the deletion or inactivation of glycerol kinase and glycerol dehydrogenase activities in the preferred production organism.

Media and Carbon Substrates

[0074] Fermentation media in the present invention must contain suitable carbon substrates. Suitable substrates may include but are not limited to monosaccharides such as glucose and fructose, oligosaccharides such as lactose or sucrose, polysaccharides such as starch or cellulose or mixtures thereof and unpurified mixtures from renewable feedstocks such as cheese whey permeate, cornsteep liquor, sugar beet molasses, and barley malt. Additionally, the carbon substrate may also be one-carbon substrates such as carbon dioxide, or methanol for which metabolic conversion into key biochemical intermediates has been demonstrated.

[0075] Glycerol production from single carbon sources (e.g., methanol, formaldehyde or formate) has been reported in methylotrophic yeasts (Yamada et al. (1989), *Agric. Biol. Chem.*, 53(2):541-543) and in bacteria (Hunter et al. (1985), *Biochemistry*, 24:4148-4155). These organisms can assimilate single carbon compounds, ranging in oxidation state from methane to formate, and produce glycerol. The pathway of carbon assimilation can be through ribulose monophosphate, through serine, or through xylulose-monophosphate (Gottschalk, *Bacterial Metabolism*, Second Edition, Springer-Verlag: New York (1986)). The ribulose monophosphate pathway involves the condensation of formate with ribulose-5-phosphate to form a 6 carbon sugar that becomes fructose and eventually the three carbon product, glyceraldehyde-3-phosphate. Likewise, the serine pathway assimilates the one-carbon compound into the glycolytic path-

way via methylenetetrahydrofolate.

[0076] In addition to one and two carbon substrates, methylotrophic organisms are also known to utilize a number of other carbon-containing compounds such as methylamine, glucosamine and a variety of amino acids for metabolic activity. For example, methylotrophic yeast are known to utilize the carbon from methylamine to form trehalose or glycerol (Bellion et al. (1993), *Microb. Growth C1 Compd.* , [Int. Symp.], 7th, 415-32. Editor(s): Murrell, J. Collin; Kelly, Don P. Publisher: Intercept, Andover, UK). Similarly, various species of *Candida* will metabolize alanine or oleic acid (Sulter et al. (1990), *Arch. Microbiol.* , 153(5):485-9). Hence, the source of carbon utilized in the present invention may encompass a wide variety of carbon-containing substrates and will only be limited by the choice of organism.

[0077] Although all of the above mentioned carbon substrates and mixtures thereof are suitable in the present invention, preferred carbon substrates are monosaccharides, oligosaccharides, polysaccharides, single-carbon substrates or mixtures thereof. More preferred are sugars such as glucose, fructose, sucrose, maltose, lactose and single carbon substrates such as methanol and carbon dioxide. Most preferred as a carbon substrate is glucose.

[0078] In addition to an appropriate carbon source, fermentation media must contain suitable minerals, salts, cofactors, buffers and other components, known to those skilled in the art, suitable for the growth of the cultures and promotion of the enzymatic pathway necessary for glycerol production.

Culture Conditions

[0079] Typically cells are grown at 30 °C in appropriate media. Preferred growth media are common commercially prepared media such as Luria Bertani (LB) broth, Sabouraud Dextrose (SD) broth, or Yeast medium (YM) broth. Other defined or synthetic growth media may also be used and the appropriate medium for growth of the particular microorganism will be known by one skilled in the art of microbiology or fermentation science. The use of agents known to modulate catabolite repression directly or indirectly, e.g., cyclic adenosine 3' :5'-monophosphate, may also be incorporated into the reaction media. Similarly, the use of agents known to modulate enzymatic activities (e.g., sulfites, bisulfites, and alkalis) that lead to enhancement of glycerol production may be used in conjunction with or as an alternative to genetic manipulations.

[0080] Suitable pH ranges for the fermentation are between pH 5.0 to pH 9.0 where the range of pH 6.0 to pH 8.0 is preferred for the initial condition.

[0081] Reactions may be performed under aerobic or anaerobic conditions where anaerobic or microaerobic conditions are preferred.

Identification of G3PDH, glycerol dehydrogenase, G3P phosphatase, and glycerol kinase activities

[0082] The levels of expression of the proteins G3PDH, G3P phosphatase, glycerol dehydrogenase, and glycerol kinase are measured by enzyme assays. Generally, G3PDH activity and glycerol dehydrogenase activity assays rely on the spectral properties of the cosubstrate, NADH, in the DHAP conversion to G-3-P and the DHA conversion to glycerol, respectively. NADH has intrinsic UV/vis absorption and its consumption can be monitored spectrophotometrically at 340 nm. G3P phosphatase activity can be measured by any method of measuring the inorganic phosphate liberated in the reaction. The most commonly used detection method uses the visible spectroscopic determination of a blue-colored phosphomolybdate ammonium complex. Glycerol kinase activity can be measured by the detection of G3P from glycerol and ATP, for example, by NMR. Assays can be directed toward more specific characteristics of individual enzymes if necessary, for example, by the use of alternate cofactors.

Identification and recovery of glycerol and other products (e.g. 1,3-propanediol)

[0083] Glycerol and other products (e.g. 1,3-propanediol) may be identified and quantified by high performance liquid chromatography (HPLC) and gas chromatography/mass spectroscopy (GC/MS) analyses on the cell-free extracts. Preferred is a HPLC method where the fermentation media are analyzed on an analytical ion exchange column using a mobile phase of 0.01N sulfuric acid in an isocratic fashion.

[0084] Methods for the recovery of glycerol from fermentation media are known in the art. For example, glycerol can be obtained from cell media by subjecting the reaction mixture to the following sequence of steps: filtration; water removal; organic solvent extraction; and fractional distillation (U.S. Patent No. 2,986,495).

Description Of The Preferred Embodiments

Production of Glycerol

[0085] The present invention describes a method for the production of glycerol from a suitable carbon source utilizing

a recombinant organism. Particularly suitable in the invention is a bacterial host cell, transformed with an expression cassette carrying either or both of a gene that encodes a protein having a glycerol-3-phosphate dehydrogenase activity and a gene encoding a protein having a glycerol-3-phosphatase activity. In addition to the G3PDH and G3P phosphatase genes, the host cell will contain disruptions in either or both of genes encoding endogenous glycerol kinase and glycerol dehydrogenase enzymes. The combined effect of the foreign G3PDH and G3P phosphatase genes (providing a pathway from the carbon source to glycerol) with the gene disruptions (blocking the conversion of glycerol) results in an organism that is capable of efficient and reliable glycerol production.

[0086] Although the optimal organism for glycerol production contains the above mentioned gene disruptions, glycerol production is possible with a host cell containing either one or both of the foreign G3PDH and G3P phosphatase genes in the absence of such disruptions. For example, the recombinant *E. coli* strain AA200 carrying the DAR1 gene (Example 1) was capable of producing between 0.38 g/L and 0.48 g/L of glycerol depending on fermentation parameters. Similarly, the *E. coli* DH5 α , carrying and expressible GPP2 gene (Example 2), was capable of 0.2 g/L of glycerol production. Where both genes are present, (Example 3 and 4), glycerol production attained about 40 g/L. Where both genes are present in conjunction with an elimination of the endogenous glycerol kinase activity, a reduction in the conversion of glycerol may be seen (Example 8). Furthermore, the presence of glycerol dehydrogenase activity is linked to the conversion of glycerol under glucose-limited conditions; thus, it is anticipated that the elimination of glycerol dehydrogenase activity will result in the reduction of glycerol conversion (Example 8).

Production of 1,3-propanediol

[0087] The present invention may also be adapted for the production of 1,3-propanediol by utilizing recombinant organisms expressing the foreign G3PDH and/or G3P phosphatase genes and containing disruptions in the endogenous glycerol kinase and/or glycerol dehydrogenase activities. Additionally, the invention provides for the process for the production of 1,3-propanediol from a recombinant organism where multiple copies of endogenous genes are introduced. In addition to these genetic alterations, the production cell will require the presence of a gene encoding an active dehydratase enzyme. The dehydratase enzyme activity may either be a glycerol dehydratase or a diol dehydratase. The dehydratase enzyme activity may result from either the expression of an endogenous gene or from the expression of a foreign gene transfected into the host organism. Isolation and expression of genes encoding suitable dehydratase enzymes are well known in the art and are taught by applicants in PCT/US96/06705, filed 5 November 1996 and U.S. 5686276 and U.S. 5633362, hereby incorporated by reference. It will be appreciated that, as glycerol is a key intermediate in the production of 1,3-propanediol, where the host cell contains a dehydratase activity in conjunction with expressed foreign G3PDH and/or G3P phosphatase genes and in the absence of the glycerol-converting glycerol kinase or glycerol dehydrogenase activities, the cell will be particularly suited for the production of 1,3-propanediol.

[0088] The present invention is further defined in the following Examples. It should be understood that these Examples, while indicating preferred embodiments of the invention, are given by way of illustration only. From the above discussion and these Examples, one skilled in the art can ascertain the essential characteristics of this invention, and without departing from the spirit and scope thereof, can make various changes and modifications of the invention to adapt it to various usages and conditions.

EXAMPLES

GENERAL METHODS

[0089] Procedures for phosphorylations, ligations, and transformations are well known in the art. Techniques suitable for use in the following examples may be found in Sambrook et al., *Molecular Cloning: A Laboratory Manual*, Second Edition, Cold Spring Harbor Laboratory Press (1989).

[0090] Materials and methods suitable for the maintenance and growth of bacterial cultures are well known in the art. Techniques suitable for use in the following examples may be found in *Manual of Methods for General Bacteriology* (Phillipp Gerhardt, R. G. E. Murray, Ralph N. Costilow, Eugene W. Nester, Willis A. Wood, Noel R. Krieg and G. Briggs Phillips, eds), American Society for Microbiology, Washington, DC. (1994) or in *Biotechnology: A Textbook of Industrial Microbiology* (Thomas D. Brock, Second Edition (1989) Sinauer Associates, Inc., Sunderland, MA). All reagents and materials used for the growth and maintenance of bacterial cells were obtained from Aldrich Chemicals (Milwaukee, WI), DIFCO Laboratories (Detroit, MI), GIBCO/BRL (Gaithersburg, MD), or Sigma Chemical Company (St. Louis, MO) unless otherwise specified.

[0091] The meaning of abbreviations is as follows: "h" means hour(s), "min" means minute(s), "sec" means second (s), "d" means day(s), "mL" means milliliters, "L" means liters.

Cell strains

[0092] The following *Escherichia coli* strains were used for transformation and expression of G3PDH and G3P phosphatase. Strains were obtained from the *E. coli* Genetic Stock Center, ATCC, or Life Technologies (Gaithersburg, MD).

5 [0093] AA200 (*garB10 fhuA22 ompF627 fadL701 relA1 pit-10 spoT1 tpi-1 phoM510 mcrB1*) (Anderson et al., (1970), *J. Gen. Microbiol.*, 62:329).

[0094] BB20 (*tonA22 ΔphoA8 fadL701 relA1 glpR2 glpD3 pit-10 gpsA20 spoT1 T2R*) (Cronan et al. , *J. Bact.*, 118: 598).

10 [0095] DH5 α (*deoR endA1 gyrA96 hsdR17 recA1 relA1 supE44 thi-1 Δ(lacZYA-argFV169) phi80lacZΔM15 F⁻*) (Woodcock et al., (1989), *Nucl. Acids Res.*, 17:3469).

[0096] FM5 *Escherichia coli* (ATCC 53911)

Identification of Glycerol

15 [0097] The conversion of glucose to glycerol was monitored by HPLC and/or GC. Analyses were performed using standard techniques and materials available to one of skill in the art of chromatography. One suitable method utilized a Waters Maxima 820 HPLC system using UV (210 nm) and RI detection. Samples were injected onto a Shodex SH-1011 column (8 mm x 300 mm; Waters, Milford, MA) equipped with a Shodex SH-1011P precolumn (6 mm x 50 mm), temperature-controlled at 50 °C, using 0.01 N H₂SO₄ as mobile phase at a flow rate of 0.69 mL/min. When quantitative analysis was desired, samples were prepared with a known amount of trimethylacetic acid as an external standard. Typically, the retention times of 1,3-propanediol (RI detection), glycerol (RI detection) and glucose (RI detection) were 21.39 min, 17.03 min and 12.66 min, respectively.

20 [0098] Glycerol was also analyzed by GC/MS. Gas chromatography with mass spectrometry detection for separation and quantitation of glycerol was performed using a DB-WAX column (30 m, 0.32 mm I.D., 0.25 um film thickness, J & W Scientific, Folsom, CA) at the following conditions: injector: split, 1:15; sample volume: 1 μ L; temperature profile: 150 °C intitial temperature with 30 sec hold, 40 °C/min to 180 °C, 20 °C/min to 240 °C, hold for 2.5 min. Detection: EI Mass Spectrometry (Hewlett Packard 5971, San Fernando, CA), quantitative SIM using ions 61 m/z and 64 m/z as target ions for glycerol and glycerol-d8, and ion 43 m/z as qualifier ion for glycerol. Glycerol-d8 was used as an internal standard.

Assay for glycerol-3-phosphatase, G3P phosphatase

30 [0099] The assay for enzyme activity was performed by incubating the extract with an organic phosphate substrate in a bis-Tris or MES and magnesium buffer, pH 6.5. The substrate used was either 1- α -glycerol phosphate, or d,1- α -glycerol phosphate. The final concentrations of the reagents in the assay are: buffer (20 mM bis-Tris or 50 mM MES); MgCl₂ (10 mM); and substrate (20 mM). If the total protein in the sample was low and no visible precipitation occurs with an acid quench, the sample was conveniently assayed in the cuvette. This method involved incubating an enzyme sample in a cuvette that contained 20 mM substrate (50 μ L, 200 mM), 50 mM MES, 10 mM MgCl₂, pH 6.5 buffer. The final phosphatase assay volume was 0.5 mL. The enzyme-containing sample was added to the reaction mixture; the 40 contents of the cuvette were mixed and then the cuvette was placed in a circulating water bath at T = 37 °C for 5 to 120 min, the length of time depending on whether the phosphatase activity in the enzyme sample ranged from 2 to 0.02 U/mL. The enzymatic reaction was quenched by the addition of the acid molybdate reagent (0.4 mL). After the Fiske SubbaRow reagent (0.1 mL) and distilled water (1.5 mL) were added, the solution was mixed and allowed to 45 develop. After 10 min, to allow full color development, the absorbance of the samples was read at 660 nm using a Cary 219 UV/Vis spectrophotometer. The amount of inorganic phosphate released was compared to a standard curve that was prepared by using a stock inorganic phosphate solution (0.65 mM) and preparing 6 standards with final inorganic phosphate concentrations ranging from 0.026 to 0.130 μ mol/mL.

Spectrophotometric Assay for Glycerol 3-Phosphate Dehydrogenase (G3PDH) Activity

50 [0100] The following procedure was used as modified below from a method published by Bell et al. (1975), *J. Biol. Chem.*, 250:7153-8. This method involved incubating an enzyme sample in a cuvette that contained 0.2 mM NADH; 2.0 mM dihydroxyacetone phosphate (DHAP), and enzyme in 0.1 M Tris/HCl, pH 7.5 buffer with 5 mM DTT,in a total volume of 1.0 mL at 30 °C. The spectrophotometer was set to monitor absorbance changes at the fixed wavelength of 340 nm. The instrument was blanked on a cuvette containing buffer only. After the enzyme was added to the cuvette, an absorbance reading was taken. The first substrate, NADH (50 μ L 4 mM NADH; absorbance should increase approx 1.25 AU), was added to determine the background rate. The rate should be followed for at least 3 min. The second substrate, DHAP (50 μ L 40 mM DHAP), was then added and the absorbance change over time was monitored for at

least 3 min to determine to determine the gross rate. G3PDH activity was defined by subtracting the background rate from the gross rate.

13C-NMR Assay for Glycerol Kinase Activity

[0101] An appropriate amount of enzyme, typically a cell-free crude extract, was added to a reaction mixture containing 40 mM ATP, 20 mM MgSO₄, 21 mM uniformly ¹³C labelled glycerol (99%, Cambridge Isotope Laboratories), and 0.1 M Tris-HCl, pH 9 for 75 min at 25 °C. The conversion of glycerol to glycerol 3-phosphate was detected by ¹³C-NMR (125 MHz): glycerol (63.11 ppm, d, J = 41 Hz and 72.66 ppm, t, J = 41 Hz); glycerol 3-phosphate (62.93 ppm, d, J = 41 Hz; 65.31 ppm, br d, J = 43 Hz; and 72.66 ppm, dt, J = 6, 41 Hz).

NADH-linked Glycerol Dehydrogenase Assay

[0102] NADH -linked glycerol dehydrogenase activity in *E. coli* strains (*gldA*) was determined after protein separation by non-denaturing polyacrylamide gel electrophoresis. The conversion of glycerol plus NAD⁺ to dihydroxyacetone plus NADH was coupled with the conversion of 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) to a deeply colored formazan, using phenazine methosulfate (PMS) as mediator. (Tang et al. (1997) *J. Bacteriol.* 140:182).

[0103] Electrophoresis was performed in duplicate by standard procedures using native gels (8-16% TG, 1.5 mm, 15 lane gels from Novex, San Diego, CA). Residual glycerol was removed from the gels by washing 3x with 50 mM Tris or potassium carbonate buffer, pH 9 for 10 min. The duplicate gels were developed, with and without glycerol (approx. 0.16 M final concentration), in 15 mL of assay solution containing 50 mM Tris or potassium carbonate, pH 9, 60 mg ammonium sulfate, 75 mg NAD⁺, 1.5 mg MTT, and 0.5 mg PMS.

[0104] The presence or absence of NADH -linked glycerol dehydrogenase activity in *E. coli* strains (*gldA*) was also determined, following polyacrylamide gel electrophoresis, by reaction with polyclonal antibodies raised to purified *K. pneumoniae* glycerol dehydrogenase (*dhaD*).

PLASMID CONSTRUCTION AND STRAIN CONSTRUCTION

Cloning and expression of glycerol 3-phosphatase for increase of glycerol production in *E. coli* DH5α and FM5

[0105] The *Saccharomyces cerevisiae* chromosome V lambda clone 6592 (Gene Bank, accession # U18813x11) was obtained from ATCC. The glycerol 3-phosphate phosphatase (GPP2) gene was cloned by cloning from the lambda clone as target DNA using synthetic primers (SEQ ID NO:16 with SEQ ID NO:17) incorporating an BamHI-RBS-XbaI site at the 5' end and a SmaI site at the 3' end. The product was subcloned into pCR-Script (Stratagene, Madison, WI) at the SrfI site to generate the plasmids pAH15 containing GPP2. The plasmid pAH15 contains the GPP2 gene in the inactive orientation for expression from the lac promoter in pCR-Script SK+. The BamHI-SmaI fragment from pAH15 containing the GPP2 gene was inserted into pBlueScriptII SK+ to generate plasmid pAH 19. The pAH 19 contains the GPP2 gene in the correct orientation for expression from the lac promoter. The XbaI-PstI fragment from pAH19 containing the GPP2 gene was inserted into pPHOX2 to create plasmid pAH21. The pAH21/ DH5α is the expression plasmid.

Plasmids for the over-expression of DAR1 in *E. coli*

[0106] DAR1 was isolated by PCR cloning from genomic *S. cerevisiae* DNA using synthetic primers (SEQ ID NO:18 with SEQ ID NO:19). Successful PCR cloning places an Ncol site at the 5' end of DAR1 where the ATG within Ncol is the DAR1 initiator methionine. At the 3' end of DAR1 a BamHI site is introduced following the translation terminator. The PCR fragments were digested with Ncol + BamHI and cloned into the same sites within the expression plasmid pTrc99A (Pharmacia, Piscataway, NJ) to give pDAR1A.

[0107] In order to create a better ribosome binding site at the 5' end of DAR1, an Spel-RBS-Ncol linker obtained by annealing synthetic primers (SEQ ID NO:20 with SEQ ID NO:21) was inserted into the Ncol site of pDAR1A to create pAH40. Plasmid pAH40 contains the new RBS and DAR1 gene in the correct orientation for expression from the trc promoter of pTrc99A (Pharmacia, Piscataway, NJ). The Ncol-BamHI fragment from pDAR1A and a second set of Spel-RBS-Ncol linker obtained by annealing synthetic primers (SEQ ID NO:22 with SEQ ID NO:23) was inserted into the Spel-BamHI site of pBC-SK+ (Stratagene, Madison, WI) to create plasmid pAH42. The plasmid pAH42 contains a chloramphenicol resistant gene.

Construction of expression cassettes for DAR1 and GPP2

[0108] Expression cassettes for DAR1 and GPP2 were assembled from the individual DAR1 and GPP2 subclones

described above using standard molecular biology methods. The BamHI-PstI fragment from pAH19 containing the ribosomal binding site (RBS) and GPP2 gene was inserted into pAH40 to create pAH43. The BamHI-PstI fragment from pAH19 containing the RBS and GPP2 gene was inserted into pAH42 to create pAH45.

[0109] The ribosome binding site at the 5' end of GPP2 was modified as follows. A BamHI-RBS-Spel linker, obtained by annealing synthetic primers GATCCAGGAAACAGA (SEQ ID NO:24) with CTAGTCTGTTCCCTG (SEQ ID NO:25) to the XbaI-PstI fragment from pAH19 containing the GPP2 gene, was inserted into the BamHI-PstI site of pAH40 to create pAH48. Plasmid pAH48 contains the DAR1 gene, the modified RBS, and the GPP2 gene in the correct orientation for expression from the trc promoter of pTrc99A (Pharmacia, Piscataway, NJ).

10 Transformation of *E. coli*

[0110] All the plasmids described here were transformed into *E. coli* DH5 α or FM5 using standard molecular biology techniques. The transformants were verified by its DNA RFLP pattern.

15 EXAMPLE 1

PRODUCTION OF GLYCEROL FROM *E. COLI* TRANSFORMED WITH G3PDH GENE

20 Media

[0111] Synthetic media was used for anaerobic or aerobic production of glycerol using *E. coli* cells transformed with pDAR1A. The media contained per liter 6.0 g Na₂HPO₄, 3.0 g KH₂PO₄, 1.0 g NH₄Cl, 0.5 g NaCl, 1 mL 20% MgSO₄·7H₂O, 8.0 g glucose, 40 mg casamino acids, 0.5 ml 1% thiamine hydrochloride, 100 mg ampicillin.

25 Growth Conditions

[0112] Strain AA200 harboring pDAR1A or the pTrc99A vector was grown in aerobic conditions in 50 mL of media shaking at 250 rpm in 250 mL flasks at 37 °C. At A₆₀₀ 0.2-0.3 isopropylthio- β -D-galactoside was added to a final concentration of 1 mM and incubation continued for 48 h. For anaerobic growth samples of induced cells were used to fill Falcon #2054 tubes which were capped and gently mixed by rotation at 37 °C for 48 h. Glycerol production was determined by HPLC analysis of the culture supernatants. Strain pDAR1A/AA200 produced 0.38 g/L glycerol after 48 h under anaerobic conditions, and 0.48 g/L under aerobic conditions.

35 EXAMPLE 2

PRODUCTION OF GLYCEROL FROM *E. COLI* TRANSFORMED WITH G3P PHOSPHATASE GENE (GPP2)

Media

[0113] Synthetic phoA media was used in shake flasks to demonstrate the increase of glycerol by GPP2 expression in *E. coli*. The phoA medium contained per liter: Amisoy, 12 g; ammonium sulfate, 0.62 g; MOPS, 10.5 g; Na-citrate, 1.2 g; NaOH (1 M), 10 mL; 1 M MgSO₄, 12 mL; 100X trace elements, 12 mL; 50% glucose, 10 mL; 1% thiamine, 10 mL; 100 mg/mL L-proline, 10 mL; 2.5 mM FeCl₃, 5 mL; mixed phosphates buffer, 2 mL (5 mL 0.2 M NaH₂PO₄ + 9 mL 0.2 M K₂HPO₄), and pH to 7.0. The 100X traces elements for phoA medium /L contained: ZnSO₄·7 H₂O, 0.58 g; MnSO₄·H₂O, 0.34 g; CuSO₄·5 H₂O, 0.49 g; CoCl₂·6 H₂O, 0.47 g; H₃BO₃, 0.12 g, NaMoO₄·2 H₂O, 0.48 g.

Shake Flasks Experiments

[0114] The strains pAH21/DH5 α (containing GPP2 gene) and pPHOX2/DH5 α (control) were grown in 45 mL of media (phoA media, 50 ug/mL carbenicillin, and 1 ug/mL vitamin B₁₂) in a 250 mL shake flask at 37 °C. The cultures were grown under aerobic condition (250 rpm shaking) for 24 h. Glycerol production was determined by HPLC analysis of the culture supernatant. pAH21/DH5 α produced 0.2 g/L glycerol after 24 h.

EXAMPLE 3PRODUCTION OF GLYCEROL FROM D-GLUCOSE USING RECOMBINANT *E. COLI* CONTAINING BOTH GPP2 AND DAR1

[0115] Growth for demonstration of increased glycerol production by *E. coli* DH5 α -containing pAH43 proceeds aerobically at 37 °C in shake-flask cultures (erlenmeyer flasks, liquid volume 1/5th of total volume).

[0116] Cultures in minimal media/1% glucose shake-flasks are started by inoculation from overnight LB/1% glucose culture with antibiotic selection. Minimal media are: filter-sterilized defined media, final pH 6.8 (HCl), contained per liter: 12.6 g (NH₄)₂SO₄, 13.7 g K₂HPO₄, 0.2 g yeast extract (Difco), 1 g NaHCO₃, 5 mg vitamin B₁₂, 5 mL Modified Balch's Trace-Element Solution (the composition of which can be found in Methods for General and Molecular Bacteriology (P. Gerhardt et al., eds, p. 158, American Society for Microbiology, Washington, DC (1994)). The shake-flasks are incubated at 37 °C with vigorous shaking for overnight, after which they are sampled for GC analysis of the supernatant. The pAH43/DH5 α showed glycerol production of 3.8 g/L after 24 h.

EXAMPLE 4PRODUCTION OF GLYCEROL FROM D-GLUCOSE USING RECOMBINANT *E. COLI* CONTAINING BOTH GPP2 AND DAR1

[0117] Example 4 illustrates the production of glucose from the recombinant *E. coli* DH5 α /pAH48, containing both the GPP2 and DAR1 genes.

[0118] The strain DH5 α /pAH48 was constructed as described above in the GENERAL METHODS.

Pre-Culture

[0119] DH5 α /pAH48 were pre-cultured for seeding into a fermentation run. Components and protocols for the pre-culture are listed below.

Pre-Culture Media	
KH ₂ PO ₄	30.0 g/L
Citric acid	2.0 g/L
MgSO ₄ ·7H ₂ O	2.0 g/L
98% H ₂ SO ₄	2.0 mL/L
Ferric ammonium citrate	0.3 g/L
CaCl ₂ ·2H ₂ O	0.2 g/L
Yeast extract	5.0 g/L
Trace metals	5.0 mL/L
Glucose	10.0 g/L
Carbenicillin	100.0 mg/L

[0120] The above media components were mixed together and the pH adjusted to 6.8 with NH₄OH. The media was then filter sterilized.

[0121] Trace metals were used according to the following recipe:

Citric acid, monohydrate	4.0 g/L
MgSO ₄ ·7H ₂ O	3.0 g/L
MnSO ₄ ·H ₂ O	0.5 g/L
NaCl	1.0 g/L
FeSO ₄ ·7H ₂ O	0.1 g/L
CoCl ₂ ·6H ₂ O	0.1 g/L
CaCl ₂	0.1 g/L
ZnSO ₄ ·7H ₂ O	0.1 g/L
CuSO ₄ ·5 H ₂ O	10 mg/L
AlK(SO ₄) ₂ ·12H ₂ O	10 mg/L

(continued)

5	H ₃ BO ₃	10 mg/L
	Na ₂ MoO ₄ ·2H ₂ O	10 mg/L
	NiSO ₄ ·6H ₂ O	10 mg/L
	Na ₂ SeO ₃	10 mg/L
	Na ₂ WO ₄ ·2H ₂ O	10 mg/L

10 [0122] Cultures were started from seed culture inoculated from 50 µL frozen stock (15% glycerol as cryoprotectant) to 600 mL medium in a 2-L Erlenmeyer flask. Cultures were grown at 30 °C in a shaker at 250 rpm for approximately 12 h and then used to seed the fermenter.

Fermentation growth	
Vessel	
15	15-L stirred tank fermenter
Medium	
20	KH ₂ PO ₄ 6.8 g/L
	Citric acid 2.0 g/L
	MgSO ₄ ·7H ₂ O 2.0 g/L
	98% H ₂ SO ₄ 2.0 mL/L
25	Ferric ammonium citrate 0.3 g/L
	CaCl ₂ ·2H ₂ O 0.2 g/L
	Mazu DF204 antifoam 1.0 mL/L

30 [0123] The above components were sterilized together in the fermenter vessel. The pH was raised to 6.7 with NH₄OH. Yeast extract (5 g/L) and trace metals solution (5 mL/L) were added aseptically from filter sterilized stock solutions. Glucose was added from 60% feed to give final concentration of 10 g/L. Carbenicillin was added at 100 mg/L. Volume after inoculation was 6 L.

Environmental Conditions For Fermentation

35 [0124] The temperature was controlled at 36 °C and the air flow rate was controlled at 6 standard liters per minute. Back pressure was controlled at 0.5 bar. The agitator was set at 350 rpm. Aqueous ammonia was used to control pH at 6.7. The glucose feed (60% glucose monohydrate) rate was controlled to maintain excess glucose.

Results

40 [0125] The results of the fermentation run are given in Table 1.

Table 1

EFT (hr)	OD550 (AU)	[Glucose] (g/L)	[Glycerol] (g/L)	Total Glucose Fed (g)	Total Glycerol Produced (g)
0	0.8	9.3		25	
6	4.7	4.0	2.0	49	14
8	5.4	0	3.6	71	25
50	10	6.7	0.0	116	33
	12	7.4	2.1	157	49
	14.2	10.4	0.3	230	70
	16.2	18.1	9.7	259	106
55	18.2	12.4	14.5	305	
	20.2	11.8	17.4	353	119
	22.2	11.0	12.6	382	

Table 1 (continued)

EFT (hr)	OD550 (AU)	[Glucose] (g/L)	[Glycerol] (g/L)	Total Glucose Fed (g)	Total Glycerol Produced (g)
5	24.2	10.8	6.5	26.6	404
	26.2	10.9	6.8		442
	28.2	10.4	10.3	31.5	463
	30.2	10.2	13.1	30.4	493
	32.2	10.1	8.1	28.2	512
	34.2	10.2	3.5	33.4	530
	36.2	10.1	5.8		548
	38.2	9.8	5.1	36.1	512
10					233

EXAMPLE 5

ENGINEERING OF GLYCEROL KINASE MUTANTS OF *E. COLI* FM5 FOR PRODUCTION OF GLYCEROL FROM GLUCOSEConstruction of integration plasmid for glycerol kinase gene replacement in *E. coli* FM5

[0126] *E. coli* FM5 genomic DNA was prepared using the Puregene DNA Isolation Kit (Gentra Systems, Minneapolis, MN). A 1.0 kb DNA fragment containing partial *glpF* and glycerol kinase (*glpK*) genes was amplified by PCR (Mullis and Falloona, *Methods Enzymol.*, 155:335-350, 1987) from FM5 genomic DNA using primers SEQ ID NO:26 and SEQ ID NO:27. A 1.1 kb DNA fragment containing partial *glpK* and *glpX* genes was amplified by PCR from FM5 genomic DNA using primers SEQ ID NO:28 and SEQ ID NO:29. A *Mun*I site was incorporated into primer SEQ ID NO:28. The 5' end of primer SEQ ID NO:28 was the reverse complement of primer SEQ ID NO:27 to enable subsequent overlap extension PCR. The gene splicing by overlap extension technique (Horton et al., *BioTechniques*, 8:528-535, 1990) was used to generate a 2.1 kb fragment by PCR using the above two PCR fragments as templates and primers SEQ ID NO:26 and SEQ ID NO:29. This fragment represented a deletion of 0.8 kb from the central region of the 1.5 kb *glpK* gene. Overall, this fragment had 1.0 kb and 1.1 kb flanking regions on either side of the *Mun*I cloning site (within the partial *glpK*) to allow for chromosomal gene replacement by homologous recombination.

[0127] The above 2.1 kb PCR fragment was blunt-ended (using mung bean nuclease) and cloned into the pCR-Blunt vector using the Zero Blunt PCR Cloning Kit (Invitrogen, San Diego, CA) to yield the 5.6 kb plasmid pRN100 containing kanamycin and Zeocin resistance genes. The 1.2 kb *Hinc*II fragment from pLoxCat1 (unpublished results), containing a chloramphenicol-resistance gene flanked by bacteriophage P1 *loxP* sites (Snaith et al., *Gene*, 166:173-174, 1995), was used to interrupt the *glpK* fragment in plasmid pRN100 by ligating it to *Mun*I-digested (and blunt-ended) plasmid pRN100 to yield the 6.9 kb plasmid pRN101-1. A 376 bp fragment containing the R6K origin was amplified by PCR from the vector pGP704 (Miller and Mekalanos, *J. Bacteriol.*, 170:2575-2583, 1988) using primers SEQ ID NO:30 and SEQ ID NO:31, blunt-ended, and ligated to the 5.3 kb *Asp718*-*Aat*II fragment (which was blunt-ended) from pRN101-1 to yield the 5.7 kb plasmid pRN102-1 containing kanamycin and chloramphenicol resistance genes. Substitution of the CoIE1 origin region in pRN101-1 with the R6K origin to generate pRN102-1 also involved deletion of most of the Zeocin resistance gene. The host for pRN102-1 replication was *E. coli* SY327 (Miller and Mekalanos, *J. Bacteriol.*, 170: 2575-2583, 1988) which contains the *pir* gene necessary for the function of the R6K origin.

Engineering Of Glycerol Kinase Mutant RJF10m With Chloramphenicol Resistance Gene Interrupt

[0128] *E. coli* FM5 was electrotransformed with the non-replicative integration plasmid pRN102-1 and transformants that were chloramphenicol-resistant (12.5 µg/mL) and kanamycin-sensitive (30 µg/mL) were further screened for glycerol non-utilization on M9 minimal medium containing 1 mM glycerol. An *Eco*RI digest of genomic DNA from one such mutant, RJF10m, when probed with the intact *glpK* gene via Southern analysis (Southern, *J. Mol. Biol.*, 98:503-517, 1975) indicated that it was a double-crossover integrant (*glpK* gene replacement) since the two expected 7.9 kb and 2.0 kb bands were observed, owing to the presence of an additional *Eco*RI site within the chloramphenicol resistance gene. The wild-type control yielded the single expected 9.4 kb band. A ¹³C NMR analysis of mutant RJF10m confirmed that it was incapable of converting ¹³C-labeled glycerol and ATP to glycerol-3-phosphate. This *glpK* mutant was further analyzed by genomic PCR using primer combinations SEQ ID NO:32 and SEQ ID NO:33, SEQ ID NO:34 and SEQ ID NO:35, and SEQ ID NO:32 and SEQ ID NO:35 which yielded the expected 2.3 kb, 2.4 kb, and 4.0 kb PCR fragments respectively. The wild-type control yielded the expected 3.5 kb band with primers SEQ ID NO:32 and SEQ ID NO:35.

The *glpK* mutant RJJ10m was electrotransformed with plasmid pAH48 to allow glycerol production from glucose. The *glpK* mutant *E. coli* RJJ10m has been deposited with ATCC under the terms of the Budapest Treaty on 24 November 1997.

5 Engineering Of Glycerol Kinase Mutant RJJ10 With Chloramphenicol Resistance Gene Interrupt Removed

[0129] After overnight growth on YENB medium (0.75% yeast extract, 0.8% nutrient broth) at 37 °C, *E. coli* RJJ10m in a water suspension was electrotransformed with plasmid pJW168 (unpublished results), which contained the bacteriophage P1 Cre recombinase gene under the control of the IPTG-inducible *lacUV5* promoter, a temperature-sensitive 10 pSC101 replicon, and an ampicillin resistance gene. Upon outgrowth in SOC medium at 30 °C, transformants were selected at 30 °C (permissive temperature for pJW168 replication) on LB agar medium supplemented with carbenicillin (50 µg/mL) and IPTG (1 mM). Two serial overnight transfers of pooled colonies were carried out at 30 °C on fresh LB agar medium supplemented with carbenicillin and IPTG in order to allow excision of the chromosomal chloramphenicol resistance gene via recombination at the *loxP* sites mediated by the Cre recombinase (Hoess and Abremski, *J. Mol. Biol.*, 181:351-362, 1985). Resultant colonies were replica-plated on to LB agar medium supplemented with carbenicillin and IPTG and LB agar supplemented with chloramphenicol (12.5 µg/mL) to identify colonies that were carbenicillin-resistant and chloramphenicol-sensitive indicating marker gene removal. An overnight 30 °C culture of one such colony was used to inoculate 10 mL of LB medium. Upon growth at 30 °C to OD (600 nm) of 0.6, the culture was incubated at 37 °C overnight. Several dilutions were plated on prewarmed LB agar medium and the plates incubated 15 overnight at 42 °C (the non-permissive temperature for pJW168 replication). Resultant colonies were replica-plated 20 on to LB agar medium and LB agar medium supplemented with carbenicillin (75 µg/mL) to identify colonies that were carbenicillin-sensitive indicating loss of plasmid pJW168. One such *glpK* mutant, RJJ10, was further analyzed by 25 genomic PCR using primers SEQ ID NO:32 and SEQ ID NO:35 and yielded the expected 3.0 kb band confirming marker gene excision. Glycerol non-utilization by mutant RJJ10 was confirmed by lack of growth on M9 minimal medium containing 1 mM glycerol. The *glpK* mutant RJJ10 was electrotransformed with plasmid pAH48 to allow glycerol production from glucose.

EXAMPLE 6

30 CONSTRUCTION OF *E. COLI* STRAIN WITH *GLDA* GENE KNOCKOUT

[0130] The *glcA* gene was isolated from *E. coli* by PCR (K. B. Mullis and F. A. Falloona (1987) *Meth. Enzymol.* 155: 335-350) using primers SEQ ID NO:36 and SEQ ID NO:37, which incorporate terminal Sph1 and Xba1 sites, respectively, and cloned (T. Maniatis 1982 *Molecular Cloning. A Laboratory Manual*. Cold Spring Harbor, Cold Spring Harbor, NY) between the Sph1 and Xba1 sites in pUC18, to generate pKP8. pKP8 was cut at the unique Sal1 and Nco1 sites within the *glcA* gene, the ends flushed with Klenow and religated, resulting in a 109 bp deletion in the middle of *glcA* and regeneration of a unique Sal1 site, to generate pKP9. A 1.4 kb DNA fragment containing the gene conferring kanamycin resistance (kan), and including about 400 bps of DNA upstream of the translational start codon and about 40 100 bps of DNA downstream of the translational stop codon, was isolated from pET-28a(+) (Novagen, Madison, Wis) by PCR using primers SEQ ID NO:38 and SEQ ID NO:39, which incorporate terminal Sal1 sites, and subcloned into 45 the unique Sal1 site of pKP9, to generate pKP13. A 2.1 kb DNA fragment beginning 204 bps downstream of the *glcA* translational start codon and ending 178 bps upstream of the *glcA* translational stop codon, and containing the kan insertion, was isolated from pKP13 by PCR using primers SEQ ID NO:40 and SEQ ID NO:41, which incorporate terminal Sph1 and Xba1 sites, respectively, was subcloned between the Sph1 and Xba1 sites in pMAK705 (Genencor International, Palo Alto, Calif.), to generate pMP33. *E. coli* FM5 was transformed with pMP33 and selected on 20 µg/mL kan at 30 °C, which is the permissive temperature for pMAK705 replication. One colony was expanded overnight at 30 °C 50 in liquid media supplemented with 20 µg/mL kan. Approximately 32,000 cells were plated on 20 µg/mL kan and incubated for 16 hrs at 44 °C, which is the restrictive temperature for pMAK705 replication. Transformants growing at 44 °C have plasmid integrated into the chromosome, occurring at a frequency of approximately 0.0001. PCR and Southern blot (E.M. Southern 1975 *J. Mol. Biol.* 98:503-517) analyses were used to determine the nature of the chromosomal integration events in the transformants. Western blot analysis (H. Towbin, et al. (1979) *Proc. Natl. Acad. Sci.* 76:4350) was used to determine whether glycerol dehydrogenase protein, the product of *glcA*, is produced in the transformants. An activity assay was used to determine whether glycerol dehydrogenase activity remained in the transformants. Activity in glycerol dehydrogenase bands on native gels was determined by coupling the conversion of glycerol + NAD (+) → dihydroxyacetone + NADH to the conversion of a tetrazolium dye, MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] to a deeply colored formazan, with phenazine methosulfate as mediator. Glycerol dehydrogenase also requires the presence of 30 mM ammonium sulfate and 100 mM Tris, pH 9 (C.-T. Tang, et al. (1997) *J. Bacteriol.* 140:182). Of 8 transformants analyzed, 6 were determined to be *glcA* knockouts. *E. coli* MSP33.6 has been 55

deposited with ATCC under the terms of the Budapest Treaty on 24 November 1997.

EXAMPLE 7

5 CONSTRUCTION OF *E. COLI* STRAIN WITH GLPK AND GLDA GENE KNOCKOUTS

[0131] A 1.6 kb DNA fragment containing the *gldA* gene and including 228 bps of DNA upstream of the translational start codon and 220 bps of DNA downstream of the translational stop codon was isolated from *E. coli* by PCR using primers SEQ ID NO:42 and SEQ ID NO:43, which incorporate terminal Sph1 and Xba1 sites, respectively, and cloned between the Sph1 and Xba1 sites of pUC 18, to generate pQN2. pQN2 was cut at the unique Sal1 and Nco 1 sites within the *gldA* gene, the ends flushed with Klenow and religated, resulting in a 109 bps deletion in the middle of *gldA* and regeneration of a unique Sal 1 site, to generate pQN4. A 1.2 kb DNA fragment containing the gene conferring kanamycin resistance (kan), and flanked by loxP sites was isolated from pLoxKan2 (Genencor International, Palo Alto, Calif.) as a Stu1/Xho1 fragment, the ends flushed with Klenow, and subcloned into pQN4 at the Sal1 site after flushing with Klenow, to generate pQN8. A 0.4 kb DNA fragment containing the R6K origin of replication was isolated from pGP704 (Miller and Mekalanos, *J. Bacteriol.*, 170:2575-2583, 1988) by PCR using primers SEQ ID NO:44 and SEQ ID NO:45, which incorporate terminal Sph1 and Xba1 sites, respectively, and ligated to the 2.8 kb Sph1/Xba1 DNA fragment containing the *gldA*::kan cassette from pQN8, to generate pKP22. A 1.0 kb DNA fragment containing the gene conferring chloramphenicol resistance (cam), and flanked by loxP sites was isolated from pLoxCat2 (Genencor International, Palo Alto, Calif.) as an Xba1 fragment, and subcloned into pKP22 at the Xba1 site, to generate pKP23. *E. coli* strain RJF10 (see EXAMPLE 5), which is glpK-, was transformed with pKP23 and transformants with the phenotype kanRcamS were isolated, indicating double crossover integration, which was confirmed by southern blot analysis. Glycerol dehydrogenase gel activity assays (as described in EXAMPLE 6) demonstrated that active glycerol dehydrogenase was not present in these transformants. The kan marker was removed from the chromosome using the Cre-producing plasmid pJW168, as described in EXAMPLE 5, to produce strain KLP23. Several isolates with the phenotype kanS demonstrated no glycerol dehydrogenase activity, and southern blot analysis confirmed loss of the kan marker.

30

SEQ ID NO:44:

CACGCATGCAGTTAACCTGTTGATAGTAC

35

SEQ ID NO:45:

GCGTCTAGATCCTTTAAATTAAAAATG

40 EXAMPLE 8

CONSUMPTION OF GLYCEROL PRODUCED FROM D-GLUCOSE BY RECOMBINANT *E. COLI* CONTAINING BOTH GPP2 AND DAR1 WITH AND WITHOUT GLYCEROL KINASE (GLPK) ACTIVITY

45 [0132] EXAMPLE 8 illustrates the consumption of glycerol by the recombinant *E. coli* FM5/pAH48 and RJF10/pAH48. The strains FM5/pAH48 and RJF10/pAH48 were constructed as described above in the GENERAL

METHODS.

50 Pre-Culture

[0133] FM5/pAH48 and RJF10/pAH48 were pre-cultured for seeding a fermenter in the same medium used for fermentation, or in LB supplemented with 1% glucose. Either carbenicillin or ampicillin were used (100 mg/L) for plasmid maintenance. The medium for fermentation is as described in

55

EXAMPLE 4.

[0134] Cultures were started from frozen stocks (15% glycerol as cryoprotectant) in 600 mL medium in a 2-L Erlen-

meyer flask, grown at 30 °C in a shaker at 250 rpm for approximately 12 h, and used to seed the fermenter.

Fermentation growth

5 [0135] A 15-L stirred tank fermenter with 5-7 L initial volume was prepared as described in EXAMPLE 4. Either carbenicillin or ampicillin were used (100 mg/L) for plasmid maintenance.

Environmental Conditions to Evaluate Glycerol Kinase (GlpK) Activity

10 [0136] The temperature was controlled at 30 °C and the air flow rate controlled at 6 standard liters per minute. Back pressure was controlled at 0.5 bar. Dissolved oxygen tension was controlled at 10% by stirring. Aqueous ammonia was used to control pH at 6.7. The glucose feed (60% glucose) rate was controlled to maintain excess glucose until glycerol had accumulated to at least 25 g/L. Glucose was then depleted, resulting in the net metabolism of glycerol. Table 2 shows the resulting conversion of glycerol.

15

Table 2

Conversion of glycerol by FM5/pAH48 (wt) and RJJ10/pAH48 (glpK)		
Strain	number of examples	rate of glycero consumption g/OD/hr
FM5/pAH48	2	0.095 ± 0.015
RJJ10/pAH48	3	0.021 ± 0.011

20 [0137] As is seen by the data in Table 2, the rate of glycerol consumption decreases about 4-5 fold where endogenous glycerol kinase activity is eliminated.

Environmental Conditions to Evaluate Glycerol Dehydrogenase (GldA) Activity

25 [0138] The temperature was controlled at 30 °C and the air flow rate controlled at 6 standard liters per minute. Back pressure was controlled at 0.5 bar. Dissolved oxygen tension was controlled at 10% by stirring. Aqueous ammonia was used to control pH at 6.7. In the first fermentation, glucose was kept in excess for the duration of the fermentation. The second fermentation was operated with no residual glucose after the first 25 hours. Samples over time from the two fermentations were taken for evaluation of GlpK and GldA activities. Table 3 summarizes RJJ10/pAH48 fermentations that show the effects of GldA on selectivity for glycerol.

35

Table 3

GldA and GlpK activities from two RJJ10/pAH48 fermentations				
Fermentation	Time (hrs)	GldA	GlpK	Overall selectivity (g/g)
1	25	-	-	42 %
	46	-	-	49%
	61	+	-	54%
2	25	+	-	41%
	46	++	-	14%
	61	++	-	12%

50 [0139] As is seen by the data in Table 3, the presence of glycerol dehydrogenase (GldA) activity is linked to the conversion of glycerol under glucose-limited conditions; thus, it is anticipated that eliminating glycerol dehydrogenase activity will reduce glycerol conversion.

EXAMPLE 9

PRODUCTION OF GLYCEROL FROM D-GLUCOSE USING RECOMBINANT *E. BLATTAE* CONTAINING BOTH GPP2 AND DAR1

55 [0140] Example 9 illustrates the production of glycerol from D-glucose from recombinant *E. blattae* containing both

GPP2 and DAR1 genes.

[0141] *E. blattae*, obtained from the ATCC and having ATCC accession number 33429, was grown at 30 °C until the culture reached an OD of about 0.6 AU at 600 nm. The culture was then transformed with pAH48, a plasmid comprising GPP2 and DAR1 genes (described in WO 98/21341), using electroporation techniques. The transformants were confirmed by DNA RFLP pattern and antibiotic resistance (200 ug/mL carbenicillin).

[0142] The transformed *E. blattae* was grown aerobically at 35 °C in shake-flask cultures. The cultures were grown in a defined medium plus 2% glucose with antibiotic selection and were started by inoculation from an overnight culture grown in LB plus 1 % glucose with antibiotic selection. The defined medium contained per liter: 27.2 g KH₂PO₄, 2 g citric acid, 2 g MgSO₄·7H₂O, 1.2 ml 98% H₂SO₄, 0.3 g ferric ammonium citrate, 0.2 g CaCl₂·2H₂O, 10 g yeast extract (Difco), 5 mL Modified Balch's Trace-Element Solution (the composition of which can be found in Methods for General and Molecular Bacteriology (P. Gerhardt et al., eds, p. 158, American Society for Microbiology, Washington, DC, (994)). The defined medium was filter-sterilized and adjusted to a final pH 6.8 with NH₄OH. The shake-flasks were incubated at 35 °C overnight with vigorous shaking. The supernatant was then subjected to HPLC analysis for the presence of glycerol. After the overnight incubation, the *E. blattae* containing pAH48 produced 7.63 g/L of glycerol. The control, which was wild-type *E. blattae* (ATCC 33429) grown under the same conditions, produced = 0.2 g/L of glycerol.

EXAMPLE 10

PRODUCTION OF GLYCEROL FROM D-GLUCOSE USING RECOMBINANT *E. COLI* DEFICIENT IN GLDA AND GLPK AND CONTAINING BOTH GPP2 AND DAR1 INTEGRATED INTO THE CHROMOSOME

[0143] This Example illustrates the production of glycerol from D glucose from recombinant *E. coli* with *gldA* and *glpK* gene knockouts and containing both GPP2 and DAR1 encoding genes integrated into the host cell chromosome.

[0144] *E. coli* strain KLP23, prepared as described in Example 7, is deficient in both glycerol kinase (product of *glpK*) and glycerol dehydrogenase (product of *gldA*) activities. KLP23 containing DAR1, GPP2 and a *loxP* flanked chloramphenicol resistant gene integrated into the chromosome at the *ampC* location was prepared and is referred to as AH76Rlcm.

[0145] Integration plasmids were designed and constructed based on a cre-lox integration system (Hoess, supra). In order to create the integration plasmids, a Hind III - SmaI fragment of *pLoxCat1* was inserted into Hind III and Sma I linearized pAH48 to create pAH48cm2. The pAH48 plasmid contains DAR1 and GPP2 genes expressed under the control of the *trc* promoter. The 3.5 kb ApaI I fragment of pAH48cm2 was blunt ended with T4 DNA polymerase (Boehringer Mannheim Biochemical) and dNTPs and inserted into NruI linearized *pInt-ampC* (Genencor International, CA), using *E. coli* SY327 (Miller et al., *J. Bacteriol.* 170:2575-2583, 1998) as a host to create pAH76 and pAH76R. The "R" means reverse orientation of the integration cassette. Both plasmids, pAH76 and pAH76R, contain a R6K origin of replication and are not able to replicate in KLP23. The plasmids pAH76 and pAH76R were used to transform KLP23 for integration at the *ampC* location of the *E. coli* chromosome. The transformants were selected on 10 ug/ml of chloramphenicol and were kanamycin sensitive, yielding double crossover integration. These *E. coli* transformants are named AH76lcm and AH76Rlcm.

[0146] AH76Rlcm cultures were grown in shake-flasks in defined medium (described in Example 9) plus 2.5% glucose started by inoculation from an overnight LB culture having 1% glucose and antibiotic selection. The shake-flasks (erlenmeyer flasks, liquid volume 1/5th of total volume) were incubated at 37 °C with vigorous shaking overnight, after which the supernatant was sampled for glycerol using a colormetric enzyme assay (Sigma, Procedure No. 337) on a Monarch 2000 instrument (Instrumentation Laboratory Co., Lexington, MA). AH77Rlcm showed glycerol production of 6.7 g/L after 25 hr.

[0147] *E. coli* pAH76RI has the chloramphenicol gene deleted from AH76Rlcm. The chloramphenicol gene was deleted from the chromosome using the Cre-producing plasmid, pJW168, as described in Example 5. The transformants were selected for carbenicillin resistance and chloramphenicol sensitivity under 1 mM IPTG induction at 30 °C. After removal of the chloramphenicol gene, AH76RI was grown on LB medium without any antibiotics to cure pJW168. The final version of AH76RI is not able to grow on chloramphenicol or carbenicillin selection.

[0148] AH76RI cultures were grown in shake-flasks in a defined media plus 2 % glucose started by inoculation from an overnight LB/1% glucose culture. The shake-flasks were incubated at 35 °C with vigorous shaking overnight, after which the supernatant was sampled for glycerol using a colormetric assay (Sigma, Procedure No. 337) on a Monarch 2000 instrument (Instrumentation Laboratory Co. Lexington, MA). AH77RI showed glycerol production of 4.6 g/L after 24 hr.

[0149] All the plasmids described in this example were transformed into *E. coli* KLP23 using standard molecular biology techniques. The transformants were verified by DNA RFLP pattern, antibiotic resistance, PCR amplification, or G3P phosphatase assay.

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

5

10

15

20

25

30

35

40

45

50

55




A. The indications made below relate to the microorganism referred to in the description on page <u>5</u> , line <u>20</u>	
B. IDENTIFICATION OF DEPOSIT	
Name of depositary institution AMERICAN TYPE CULTURE COLLECTION	
Address of depositary institution (including postal code and country) 10801 University Blvd. Manassas, Virginia 20110-2209 USA	
Date of deposit 26 September 1996	Accession Number ATCC98187
C. ADDITIONAL INDICATIONS (leave blank if not applicable)	
In respect of those designations in which a European patent is sought, a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample. (Rule 28(4) EPC)	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>For receiving Office use only</p> <p><input checked="" type="checkbox"/> This sheet was received with the international application</p> <p>Authorized officer </p> </div> <div style="width: 45%;"> <p>For International Bureau use only</p> <p><input type="checkbox"/> This sheet was received by the International Bureau on:</p> <p>Authorized officer</p> </div> </div>	

Form PCT/RO/134 (July 1992)

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

5

A. The indications made below relate to the microorganism referred to in the description on page <u>5</u> , line <u>21</u>													
B. IDENTIFICATION OF DEPOSIT													
Name of depositary institution AMERICAN TYPE CULTURE COLLECTION													
Address of depositary institution (including postal code and country) 10801 University Blvd. Manassas, Virginia 20110-2209 USA													
Date of deposit 6 November 1996	Accession Number ATCC98248												
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>													
In respect of those designations in which a European patent is sought, a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample. (Rule 28(4) EPC)													
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)													
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable) The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g. "Accession Number of Deposit")													
<table border="1"> <tr> <td colspan="2">For receiving Office use only</td> </tr> <tr> <td><input checked="" type="checkbox"/></td> <td>This sheet was received with the international application</td> </tr> <tr> <td colspan="2">Authorized officer </td> </tr> </table> <table border="1"> <tr> <td colspan="2">For International Bureau use only</td> </tr> <tr> <td><input type="checkbox"/></td> <td>This sheet was received by the International Bureau on:</td> </tr> <tr> <td colspan="2">Authorized officer</td> </tr> </table>		For receiving Office use only		<input checked="" type="checkbox"/>	This sheet was received with the international application	Authorized officer 		For International Bureau use only		<input type="checkbox"/>	This sheet was received by the International Bureau on:	Authorized officer	
For receiving Office use only													
<input checked="" type="checkbox"/>	This sheet was received with the international application												
Authorized officer 													
For International Bureau use only													
<input type="checkbox"/>	This sheet was received by the International Bureau on:												
Authorized officer													


Form PCT/RO/134 (July 1992)

55

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

5

<p>A. The indications made below relate to the microorganism referred to in the description on page <u>5</u>, line <u>22</u></p>	
<p>B. IDENTIFICATION OF DEPOSIT</p>	
<p>Further deposits are identified on an additional sheet <input type="checkbox"/></p>	
<p>Name of depositary institution AMERICAN TYPE CULTURE COLLECTION</p>	
<p>Address of depositary institution (including postal code and country) 10801 University Blvd. Manassas, Virginia 20110-2209 USA</p>	
<p>Date of deposit 25 November 1997</p>	
<p>Accession Number ATCC98597</p>	
<p>C. ADDITIONAL INDICATIONS (leave blank if not applicable)</p>	
<p>This information is continued on an additional sheet <input type="checkbox"/></p>	
<p>In respect of those designations in which a European patent is sought, a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample. (Rule 28(4) EPC)</p>	
<p>D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)</p>	
<p>E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)</p>	
<p>The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g. "Accession Number of Deposit")</p>	
<p>For receiving Office use only</p>	
<p><input checked="" type="checkbox"/> This sheet was received with the international application</p>	
<p>For International Bureau use only</p>	
<p><input type="checkbox"/> This sheet was received by the International Bureau on:</p>	
<p>Authorized officer</p>	
	
<p>Authorized officer</p>	




Form PCT/RO/134 (July 1992)

55

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

5

A. The indications made below relate to the microorganism referred to in the description on page <u>5</u> , line <u>23</u>									
B. IDENTIFICATION OF DEPOSIT									
Name of depositary institution AMERICAN TYPE CULTURE COLLECTION									
Address of depositary institution (including postal code and country) 10801 University Blvd. Manassas, Virginia 20110-2209 USA									
Date of deposit 25 November 1997	Accession Number ATCC98598								
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>									
In respect of those designations in which a European patent is sought, a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample. (Rule 28(4) EPC)									
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)									
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)									
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")									
<table border="0"> <tr> <td style="text-align: center;">For receiving Office use only</td> <td style="text-align: center;">For International Bureau use only</td> </tr> <tr> <td><input checked="" type="checkbox"/> This sheet was received with the international application</td> <td><input type="checkbox"/> This sheet was received by the International Bureau on:</td> </tr> <tr> <td colspan="2">  </td> </tr> <tr> <td colspan="2">Authorized officer</td> </tr> </table>		For receiving Office use only	For International Bureau use only	<input checked="" type="checkbox"/> This sheet was received with the international application	<input type="checkbox"/> This sheet was received by the International Bureau on:			Authorized officer	
For receiving Office use only	For International Bureau use only								
<input checked="" type="checkbox"/> This sheet was received with the international application	<input type="checkbox"/> This sheet was received by the International Bureau on:								
									
Authorized officer									

Form PCT/RO/134 (July 1992)

SEQUENCE LISTING

55 [0150]

(1) GENERAL INFORMATION:

(i) APPLICANT:

- (A) NAME: E. I. DU PONT DE NEMOURS AND COMPANY
- (B) STREET: 1007 MARKET STREET
- (C) CITY: WILMINGTON
- (D) STATE: DELAWARE
- (E) COUNTRY: U.S.A.
- (F) ZIP: 19898
- (G) TELEPHONE: 302-892-8112
- (H) TELEFAX: 302-773-0164
- (I) TELEX: 6717325

(ii) TITLE OF INVENTION: METHOD FOR THE PRODUCTION OF GLYCEROL BY RECOMBINANT ORGANISMS

(iii) NUMBER OF SEQUENCES: 43

(iv) COMPUTER READABLE FORM:

- (A) MEDIUM TYPE: DISKETTE, 3.5 INCH
- (B) COMPUTER: IBM PC COMPATIBLE
- (C) OPERATING SYSTEM: MICROSOFT WINDOWS 95
- (D) SOFTWARE: MICROSOFT WORD VERSION 7.0A

(v) CURRENT APPLICATION DATA:

- (A) APPLICATION NUMBER:
- (B) FILING DATE:
- (C) CLASSIFICATION:

(vi) PRIOR APPLICATION DATA:

- (A) APPLICATION NUMBER: 08/982,783
- (B) FILING DATE: DECEMBER 2, 1997
- (C) CLASSIFICATION:

(vii) ATTORNEY/AGENT INFORMATION:

- (A) NAME: FLOYD, LINDA AXAMETHY
- (B) REGISTRATION NUMBER: 33,692
- (C) REFERENCE/DOCKET NUMBER: CR-9981-C

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1380 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

5 CTTTAATTT CTTTTATCTT ACTCTCCTAC ATAAGACATC AAGAAACAAT TGTATATTGT 60
 ACACCCCCC CCTCCACAAA CACAAATATT GATAATATAA AGATGTCTGC TGCTGCTGAT 120
 10 AGATTAACACT TAACTTCCGG CCACTTGAAT GCTGGTAGAA AGAGAAGTTC CTCTTCTGTT 180
 TCTTTGAAGG CTGCCGAAAA GCCTTCAAG GTTACTGTGA TTGGATCTGG TAACTGGGGT 240
 ACTACTATTG CCAAGGTGGT TGCCGAAAAT TGTAAGGGAT ACCCAGAAGT TTTCGCTCCA 300
 ATAGTACAAA TGTGGGTGTT CGAAGAAGAG ATCAATGGTG AAAAATTGAC TGAAATCATA 360
 AATACTAGAC ATCAAAACGT GAAATACTTG CCTGGCATCA CTCTACCCGA CAATTTGGTT 420
 15 GCTAATCCAG ACTTGATTGA TTCAGTCAAG GATGTCGACA TCATCGTTT CAACATTCCA 480
 CATCAATTT TGCCCCGTAT CTGTAGCAA TTGAAAGGTC ATGTTGATTC ACACGTCAGA 540
 GCTATCTCCT GTCTAAAGGG TTTGAAGTT GGTGCTAAAG GTGTCCAATT GCTATCCTCT 600
 20 TACATCACTG AGGAACACTAGG TATTCAATGT GGTGCTCTAT CTGGTGCTAA CATTGCCACC 660
 GAAGTCGCTC AAGAACACTG GTCTGAAACA ACAGTTGCTT ACCACATTCC AAAGGATTTC 720
 25 AGAGGCGAGG GCAAGGACGT CGACCATAAG GTTCTAAAGG CCTTGTCCA CAGACCTTAC 780
 TTCCACGTTA GTGTCAATCGA AGATGTTGCT GGTATCTCCA TCTGTGGTGC TTTGAAGAAC 840
 30 GTTGTGCCT TAGGTTGTGG TTTCGTCGAA GGTCTAGGCT GGGGTAACAA CGCTTCTGCT 900
 GCCATCCAAA GAGTCGGTTT GGGTGAGATC ATCAGATTG GTCAAATGTT TTTCCCAGAA 960
 TCTAGAGAAG AAACATACTA CCAAGAGTCT GCTGGTGTG CTGATTGAT CACCACCTGC 1020
 35 GCTGGTGGTA GAAACGTCAA GGTTGCTAGG CTAATGGCTA CTTCTGGTAA GGACGCCTGG 1080
 GAATGTGAAA AGGAGTTGTT GAATGCCAA TCCGCTCAAG GTTTAATTAC CTGCAAAGAA 1140
 GTTCACGAAT GGTTGGAAAC ATGTGGCTCT GTCGAAGACT TCCCATTATT TGAAGCCGTA 1200
 40 TACCAAATCG TTTACAACAA CTACCCAATG AAGAACCTGC CGGACATGAT TGAAGAATTA 1260
 GATCTACATG AAGATTAGAT TTATTGGAGA AAGATAACAT ATCATACTTC CCCCCACTTT 1320
 45 TTGAGGCTC TTCTATATCA TATTCTAAAA TTAGCATTAT GTCATTTCTC ATAACCTACTT 1380

(2) INFORMATION FOR SEQ ID NO:2:

50 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 2946 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 55 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

5	GAATTCGAGC CTGAAGTGCT GATTACCTTC AGGTAGACTT CATCTGACC CATCAACCCC	60
10	AGCGTCAATC CTGCAAATAC ACCACCCAGC AGCACTAGGA TGATAGAGAT AATATAGTAC	120
15	GTGGTAAACGC TTGCCTCATC ACCTACGCTA TGGCCGGAAT CGGCAACATC CCTAGAATTG	180
20	AGTACGTGTG ATCCGGATAA CAACGGCAGT GAATATATCT TCGGTATCGT AAAGATGTGA	240
25	TATAAGATGA TGTATAACCA ATGAGGAGCG CCTGATCGTG ACCTAGACCT TAGTGGCAA	300
30	AACGACATAT CTATTATAGT GGGGAGAGTT TCGTGCAAAT AACAGACGCA GCAGCAAGTA	360
35	ACTGTGACGA TATCAACTCT TTTTTTATTA TGTAATAAGC AAACAAGCAC GAATGGGGAA	420
40	AGCCTATGTG CAATCACCAA GGTCGTCCT TTTTCCCCT TTGCTAATT AGAATTAAA	480
45	GAAACCAAAA GAATGAAGAA AGAAAACAAA TACTAGCCCT AACCCCTGACT TCGTTCTAT	540
50	GATAATACCC TGCTTAATG AACGGTATGC CCTAGGGTAT ATCTCACTCT GTACGTTACA	600
55	AACTCCGGTT ATTTTATCGG AACATCCGAG CACCCGGGCC TTCCCTCAACC CAGGCACCGC	660
60	CCCAGGTAAC CGTGCACGAT GAGCTAATCC TGAGCCATCA CCCACCCAC CCGTTGATGA	720
65	CAGCAATTG GAGGGCGAA AATAAAACTG GAGCAAGGAA TTACCATCAC CGTCACCATC	780
70	ACCATCATAT CGCCTTAGCC TCTAGCCATA GCCATCATGC AAGCGTGTAT CTTCTAAGAT	840
75	TCAGTCATCA TCATTACCGA GTTTGTTTC CTTCACATGA TGAAGAAGGT TTGAGTATGC	900
80	TCGAAACAAT AAGACGACGA TGGCTCTGCC ATTGGTTATA TTACGCTTT GCGGCGAGGT	960
85	GCCGATGGGT TGCTGAGGGG AAGAGTGTGTT AGCTTACGGA CCTATTGCCA TTGTTATTCC	1020
90	GATTAATCTA TTGTTCAGCA GCTCTCTCT ACCCTGTCAT TCTAGTATTT TTTTTTTTT	1080
95	TTTTGGTTT TACTTTTTT TCTTCTGCC TTTTTTCTT GTTACTTTT TTCTAGTTT	1140
100	TTTCCTTCC ACTAAGCTTT TTCTTGATT TATCCTGGG TTCTCTTTC TACTCCTTTA	1200
105	GATTTTTTT TTATATATTA ATTTTAAGT TTATGTATTT TGGTAGATTC AATTCTCTTT	1260
110	CCCTTTCTT TTCTTCGCT CCCCTTCCTT ATCAATGCTT GCTGTCAGAA GATTAACAAG	1320
115	ATACACATTC CTTAAGCGAA CGCATCCGGT GTTATATACT CGTCGTGCAT ATAAAATTT	1380

	GCCTTCAAGA TCTACTTTCC TAAGAAGATC ATTATTACAA ACACAACTGC ACTCAAAGAT	1440
5	GACTGCTCAT ACTAATATCA AACAGCACAA ACACTGTCAT GAGGACCATC CTATCAGAAG	1500
	ATCGGACTCT GCCGTGTCAA TTGTACATTT GAAACGTGCG CCCTTCAAGG TTACAGTGAT	1560
	TGGTTCTGGT AACTGGGGGA CCACCATCGC CAAAGTCATT GCGGAAAACA CAGAATTGCA	1620
10	TTCCCATATC TTCGAGCCAG AGGTGAGAAT GTGGGTTTT GATGAAAAGA TCGGCGACGA	1680
	AAATCTGACG GATATCATAA ATACAAGACA CCAGAACGTT AAATATCTAC CCAATATTGA	1740
15	CCTGCCCAT AATCTAGTGG CCGATCCTGA TCTTTACAC TCCATCAAGG GTGCTGACAT	1800
	CCTTGTTCAC AACATCCCTC ATCAATTTC ACCAACATA GTCAAACAAT TGCAAGGCCA	1860
	CGTGGCCCT CATGTAAGGG CCATCTCGTG TCTAAAGGG TTGAGTTGG GCTCCAAGGG	1920
20	TGTGCAATTG CTATCCTCCT ATGTTACTGA TGAGTTAGGA ATCCAATGTG GCGCACTATC	1980
	TGGTGCAAAC TTGGCACCGG AAGTGGCCAA GGAGCATTGG TCCGAAACCA CCGTGGCTTA	2040
	CCAACTACCA AAGGATTATC AAGGTGATGG CAAGGATGTA GATCATAAGA TTTTGAAATT	2100
25	GCTGTTCCAC AGACCTTAATC TCCACGTCAA TGTCATCGAT GATGTTGCTG GTATATCCAT	2160
	TGCCGGTGCC TTGAAGAACG TCGTGGCACT TGCATGTGGT TCGTAGAAG GTATGGGATG	2220
30	GGGTAACAAT GCCTCCGCAG CCATTCAAAG GCTGGTTTA GGTGAAATTAA TCAAGTTGG	2280
	TAGAATGTTT TTCCCAGAAT CCAAAGTCGA GACCTACTAT CAAGAATCCG CTGGTGTG	2340
	AGATCTGATC ACCACCTGCT CAGGCGGTAG AAACGTCAAG GTGCCACAT ACATGGCCAA	2400
35	GACCGGTAAG TCAGCCTTGG AAGCAGAAAA GGAATTGCTT AACGGTCAAT CCGCCCAAGG	2460
	GATAATCACA TGCAGAGAAC TTCACGGAGTG GCTACAAACA TGTGAGTTGA CCCAAGAATT	2520
	CCCAATTATT CGAGGCAGTC TACCAAGATAG TCTACAACAA CGTCCGCATG GAAGACCTAC	2580
40	CGGAGATGAT TGAAGAGCTA GACATCGATG ACGAATAGAC ACTCTCCCC CCCCTCCCC	2640
	TCTGATCTTT CCTGTTGCCT CTTTTCCCC CAACCAATTATCATTATAAC ACAAGTTCTA	2700
45	CAACTACTAC TAGTAACATT ACTACAGTTA TTATAATTCTTCTTCTTCTTAAAG	2760
	AATCTATCAT TAACGTAAAT TTCTATATAT ACATAACTAC CATTATAACAC GCTATTATCG	2820
	TTTACATATC ACATCACCGT TAATGAAAGA TACGACACCC TGTACACTAA CACAATTAAA	2880
50	TAATCGCCAT AACCTTTCT GTTATCTATA GCCCTTAAAG CTGTTCTTC GAGCTTTCA	2940
	CTGCAG	2946

55

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

5 (A) LENGTH: 3178 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

10 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

CTGCAGAACT	TCGTCTGCTC	TGTGCCATC	CTCGCGGTTA	GAAAGAAGCT	GAATTGTTTC	60
15 ATGCGCAAGG	GCATCAGCGA	GTGACCAATA	ATCACTGCAC	TAATTCCCTT	TTAGCAACAC	120
ATACTTATAT	ACAGCACCAG	ACCTTATGTC	TTTCTCTGC	TCCGATAACGT	TATCCCACCC	180
20 AACTTTTATT	TCAGTTTGG	CAGGGGAAAT	TTCACAAACCC	CGCACCGCTAA	AAATCGTATT	240
TAAACTTAAA	AGAGAACAGC	CACAAATAGG	GAACTTGGT	CTAAACGAAG	GACTCTCCCT	300
CCCTTATCTT	GACCGTGCTA	TTGCCATCAC	TGCTACAAGA	CTAAATACGT	ACTAATATAT	360
25 GTTTCGGTA	ACGAGAAAGAA	GAGCTGCCGG	TGCAGCTGCT	GCCATGGCCA	CAGCCACGGG	420
GACGCTGTAC	TGGATGACTA	GCCAAGGTGA	TAGGCCGTTA	GTGCACAATG	ACCCGAGCTA	480
CATGGTCAA	TTCCCCACCG	CCGCTCCACC	GGCAGGTCTC	TAGACGAGAC	CTGCTGGACC	540
30 GTCTGGACAA	GACGCATCAA	TTCGACGTGT	TGATCATCGG	TGGGGGGGCC	ACGGGGACAG	600
GATGTGCCCT	AGATGCTGCG	ACCAGGGAC	TCAATGTGGC	CCTTGTGAA	AAGGGGGATT	660
35 TTGCCTCGGG	AACGTCGTCC	AAATCTACCA	AGATGATTCA	CGGTGGGGTG	CGGTACTTAG	720
AGAAGGCCTT	CTGGGAGTTC	TCCAAGGCAC	AACTGGATCT	GGTCATCGAG	GCACTCAACG	780
AGCGTAAACA	TCTTATCAAC	ACTGCCCTC	ACCTGTGCAC	GGTGTACCA	ATTCTGATCC	840
40 CCATCTACAG	CACCTGGCAG	GTCCCGTACA	TCTATATGGG	CTGAAATTTC	TACGATTCT	900
TTGGCGGTTTC	CCAAAACATTG	AAAAAATCAT	ACCTACTGTC	CAAATCCGCC	ACCGTGGAGA	960
45 AGGCTCCCAT	GCTTACCAACA	GACAATTAA	AGGCCTCGCT	TGTGTACCAT	GATGGGTCCCT	1020
TTAACGACTC	GCGTTGAAC	GCCACTTTAG	CCATCACGGG	TGTGGAGAAC	GGCGCTACCG	1080
TCTTGATCTA	TGTCGAGGTA	AAAAAATTGA	TCAAAGACCC	AACTCTGGT	AAGGTTATCG	1140
50 GTGCCGAGGC	CCGGGACGTT	GAGACTAATG	AGCTTGTCAAG	AATCAACGCT	AAATGTGTGG	1200
TCAATGCCAC	GGGCCCATAC	AGTGACGCCA	TTTGCAAAT	GGACCGCAAC	CCATCCGGTC	1260
55 TGCCGGACTC	CCCGCTAAAC	GACAACCCA	AGATCAAGTC	GAACCTCAAT	CAAATCTCCG	1320
TCATGGACCC	AAAAATGGTC	ATCCCATCTA	TTGGCGTTCA	CATCGTATTG	CCCTCTTTT	1380

	ACTCCCCGAA GGATATGGGT TTGTTGGACG TCAGAACCTC TGATGCCAGA GTGATGTTCT	1440
5	TTTTACCTTG GCAGGGCAAA GTCCTGCCG GCACCCACAGA CATCCCACTA AAGCAAGTCC	1500
	CAGAAAACCC TATGCCTACA GAGGCTGATA TTCAAGATAT CTTGAAAGAA CTACAGCACT	1560
10	ATATCGAATT CCCC GTGAAA AGAGAAGACG TGCTAAGTGC ATGGGCTGGT GTCAGACCTT	1620
	TGGTCAGAGA TCCACGTACA ATCCCCGAG ACCGGAAAGAA GGGCTCTGCC ACTCAGGGCG	1680
15	TGGTAAGATC CCACTTCTTG TTCACCTCGG ATAATGGCCT AATTACTATT GCAGGTGGTA	1740
	AATGGACTAC TTACAGACAA ATGGCTGAGG AAACAGTCGA CAAAGTTGTC GAAGTTGGCG	1800
20	GATTCCACAA CCTGAAACCT TGTCACACAA GAGATATTAA GCTTGCTGGT GCAGAAGAAT	1860
	GGACGCAAAA CTATGTGGCT TTATTGGCTC AAAACTACCA TTTATCATCA AAAATGTCCA	1920
25	ACTACTTGGT TCAAAACTAC GGAACCCGTT CCTCTATCAT TTGCGAATTT TTCAAAGAAT	1980
	CCATGGAAAA TAAACTGCCT TTGTCCTTAG CCGACAAGGA AAATAACGTA ATCTACTCTA	2040
	GCGAGGGAGAA CAACTTGGTC AATTTGATA CTTTCAGATA TCCATTACACA ATCGGTGAGT	2100
30	TAAAGTATTG CATGCAGTAC GAATATTGTA GAACTCCCTT GGACTTCCTT TTAAGAAGAA	2160
	CAAGATT CGC CTTCTTGGAC GCCAAGGAAG CTTTGAATGC CGTGCATGCC ACCGTCAAAG	2220
	TTATGGGTGA TGAGTTCAAT TGTCGGAGA AAAAGAGGCA GTGGGAACCTT GAAAAAAACTG	2280
35	TGAACTTCAT CCAAGGACGT TTCGGTGTCT AAATCGATCA TGATAGTTAA GGTCGACAAA	2340
	GATAACATTC ACAAGAGTAA TAATAATGGT AATGATGATA ATAATAATAA TGATAGTAAT	2400
	AACAATAATA ATAATGGTGG TAATGGCAAT GAAATCGCTA TTATTACCTA TTTTCCTTAA	2460
40	TGGAAGAGTT AAAGTAAACT AAAAAAACTA CAAAAATATA TGAAGAAAAA AAAAAAAAGA	2520
	GGTAATAGAC TCTACTACTA CAATTGATCT TCAAATTATG ACCTTCCTAG TGTTTATATT	2580
45	CTATTTCAA TACATAATAT AATCTATATA ATCATTGCTG GTAGACTTCC GTTTAATAT	2640
	CGTTTTAATT ATCCCCTTA TCTCTAGTCT AGTTTATCA TAAAATATAG AAACACTAAA	2700
	TAATATTCTT CAAACGGTCC TGGTGCATAC GCAATACATA TTTATGGTGC AAAAAAAA	2760
50	ATGGAAAATT TTGCTAGTCA TAAACCCTT CATAAAACAA TACGTAGACA TCGCTACTTG	2820
	AAATTTCAA GTTTTATCA GATCCATGTT TCCTATCTGC CTTGACAACC TCATCGTCGA	2880
	AATAGTACCA TTTAGAACGC CCAATATTCA CATTGTGTT AAGGTCTTA TTCACCAGTG	2940
55	ACGTGTAATG GCCATGATTA ATGTGCCTGT ATGGTTAACC ACTCCAAATA GCTTATATTT	3000
	CATAGTGTCA TTGTTTTCA ATATAATGTT TAGTATCAAT GGATATGTTA CGACGGTGT	3060
	ATTTTCTTG GTCAAATCGT AATAAAATCT CGATAAAATGG ATGACTAAGA TTTTGGTAA	3120

AGTTACAAAAA TTTATCGTTT TCACTGTTGT CAATTTTG TTCTTGTAAAT CACTCGAG 3178

5 (2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

10 (A) LENGTH: 816 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

15 (ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

ATGAAACGTT	TCAATGTTT	AAAATATATC	AGAACAAACAA	AAGCAAATAT	ACAAACCATC	60
GCAATGCCTT	TGACCACAAA	ACCTTTATCT	TTGAAAATCA	ACGCCGCTCT	ATTCGATGTT	120
GACGGTACCA	TCATCATCTC	TCAACCAGCC	ATTGCTGCTT	TCTGGAGAGA	TTTCGGTAAA	180
GACAAGCCTT	ACTTCGATGC	CGAACACGTT	ATTCACATCT	CTCACGGTTG	GAGAACTTAC	240
GATGCCATTG	CCAAGTTCGC	TCCAGACTTT	GCTGATGAAG	AATACTTAA	CAAGCTAGAA	300
GGTGAAATCC	CAGAAAAGTA	CGGTGAACAC	TCCATCGAAG	TTCCAGGTGC	TGTCAAGTTG	360
TGTAATGCTT	TGAACGCCTT	GCCAAAGGAA	AAATGGGCTG	TCGCCACCTC	TGGTACCCGT	420
GACATGGCCA	AGAAATGGTT	CGACATTTG	AAGATCAAGA	GACCAGAATA	CTTCATCACC	480
GCCAATGATG	TCAAGCAAGG	TAAGCCTCAC	CCAGAACCAT	ACTTAAAGGG	TAGAAACGGT	540
TTGGGTTTCC	CAATTAATGA	ACAAGACCCA	TCCAAATCTA	AGGTTGTTGT	CTTGAAAGAC	600
GCACCAGCTG	GTATTGCTGC	TGGTAAGGCT	GCTGGCTGTA	AAATCGTTGG	TATTGCTACC	660
ACTTCGATT	TGGACTTCTT	GAAGGAAAAG	GGTTGTGACA	TCATTGTCAA	GAACCACGAA	720
TCTATCAGAG	TCGGTGAATA	CAACGCTGAA	ACCGATGAAG	TCGAATTGAT	CTTGATGAC	780
TACTTATACG	CTAAGGATGA	CTTGTGAAA	TGGTAA			816

45 (2) INFORMATION FOR SEQ ID NO:5:

50 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 753 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

5	ATGGGATTGA CTACTAAACC TCTATCTTG AAAGTTAACG CCGCTTGTT CGACGTCGAC	60
	GGTACCATTA TCATCTCTCA ACCAGCCATT GCTGCATTCT GGAGGGATTT CGGTAAGGAC	120
10		
	AAACCTTATT TCGATGCTGA ACACGTTATC CAAGTCTCGC ATGGTTGGAG AACGTTTGAT	180
15	GCCATTGCTA AGTCGCTCC AGACTTGCC AATGAAGAGT ATGTTAACAA ATTAGAAGCT	240
	GAAATTCCGG TCAAGTACGG TGAAAAATCC ATTGAAGTCC CAGGTGCAGT TAAGCTGTGC	300
	AACGCTTGA ACGCTCTACC AAAAGAGAAA TGGGCTGTGG CAACTCCGG TACCCGTGAT	360
20	ATGGCACAAA AATGGTTCGA GCATCTGGGA ATCAGGAGAC CAAAGTACTT CATTACCGCT	420
	AATGATGTCA AACAGGGTAA GCCTCATCCA GAACCATATC TGAAGGGCAG GAATGGCTTA	480
25	GGATATCCGA TCAATGAGCA AGACCCTTCC AAATCTAAGG TAGTAGTATT TGAAGACGCT	540
	CCAGCAGGTA TTGCCGCCGG AAAAGCCGCC GGTTGTAAGA TCATTGGTAT TGCCACTACT	600
	TTCGACTTGG ACTTCCTAAA GGAAAAAGGC TGTGACATCA TTGTCAAAAA CCACGAATCC	660
30	ATCAGAGTTG CGGGCTACAA TGCCGAAACA GACGAAGTTG AATTCAATT TGACGACTAC	720
	TTATATGCTA AGGACGATCT GTTGAAATGG TAA	753

35 (2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 2520 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

50

55

EP 1 034 278 B1

5	TGTATTGGCC ACGATAACCA CCCTTTGTAT ACTGTTTG TTTTCACAT GGTAAATAAC	60
	GACTTTATT AAACAACGTA TGAAAAACA TAACAAGAAT CTACCCATAC AGGCCATTTC	120
	GTAATTCTTC TCTTCTAATT GGAGTAAAC CATCAATTAA AGGGTGTGGA GTAGCATAGT	180
	GAGGGGCTGA CTGCATTGAC AAAAAATTG AAAAAAAAAGGA AAGGAAAAAGGA AAGGAAAAAA	240
10	AGACAGCCAA GACTTTAGA ACGGATAAGG TGTAATAAAA TGTGGGGGA TGCCTGTTCT	300
	CGAACCATAT AAAATATACC ATGTGGTTG AGTTGTGGCC GGAACTATAC AAATAGTTAT	360
	ATGTTCCCT CTCTCTTCCG ACTTGTAGTA TTCTCCAAAC GTTACATATT CCGATCAAGC	420
15	CAGCGCCTT ACACTAGTTT AAAACAAGAA CAGAGCCGTA TGTCCAAAT AATGGAAGAT	480
	TTACGAAGTG ACTACGTCCC GCTTATCGCC AGTATTGATG TAGGAACGAC CTCATCCAGA	540
20	TGCATTCTGT TCAACAGATG GGGCCAGGAC GTTCAAAAC ACCAAATTGA ATATTCAACT	600
	TCAGCATCGA AGGGCAAGAT TGGGGTGTCT GGCCTAAGGA GACCCTCTAC AGCCCCAGCT	660
	CGTGAAACAC CAAACGCCGG TGACATAAA ACCAGCGGAA AGCCCATCTT TTCTGCAGAA	720

25

30

35

40

45

50

55

	GGCTATGCCA TTCAAGAAC CAAATTCTA AAAATCGAGG AATTGGACTT GGACTTCCAT	780
5	AACGAACCCA CGTTGAAGTT CCCCAAACCG GGTTGGGTTG AGTGCATCC GCAGAAATTA	840
	CTGGTGAACG TCGTCCAATG CCTTGCCTCA AGTTGCTCT CTCTGCAGAC TATCAACAGC	900
	GAACGTGTAG CAAACGGTCT CCCACCTTAC AAGGTAATAT GCATGGGTAT AGCAAACATG	960
10	AGAGAAACCA CAATTCTGTG GTCCCGCCGC ACAGGAAAAC CAATTGTTAA CTACGGTATT	1020
	GTTTGGAACG ACACCAGAAC GATCAAAATC GTTAGAGACA AATGGCAAAA CACTAGCGTC	1080
	GATAGGCAAC TGCAGCTTAG ACAGAAGACT GGATTGCCAT TGCTCTCCAC GTATTTCTCC	1140
15	TGTTCCAAGC TGCGCTGGTT CCTCGACAAT GAGCCTCTGT GTACCAAGGC GTATGAGGAG	1200
	AACGACCTGA TGTCGGCAC TGTGGACACA TGGCTGATTT ACCAATTAAC TAAACAAAAG	1260
20	GCGTCGTTT CTGACGTAAC CAAAGCTTCC AGAACTGGAT TTATGAACCT CTCCACTTTA	1320
	AAGTACGACA ACGAGTTGCT GGAATTGGG GGTATTGACA AGAACCTGAT TCACATGCC	1380
	GAAATTGTGT CCTCATCTCA ATACTACGGT GACTTGGCA TTCCTGATTG GATAATGGAA	1440
25	AAGCTACACG ATTGCCCCAA AACAGTACTG CGAGATCTAG TCAAGAGAAA CCTGCCATA	1500
	CAGGGCTGTC TGGGCGACCA AAGCGCATCC ATGGTGGGGC AACTCGCTTA CAAACCCGGT	1560
	GCTGCAAAT GTACTTATGG TACCGGTTGC TTTTACTGT ACAATACGGG GACCAAAAAAA	1620
30	TTGATCTCCC AACATGGCGC ACTGACGACT CTAGCATTTC GGTTCCCACA TTTGCAAGAG	1680
	TACGGTGGCC AAAAACCAAGA ATTGAGCAAG CCACATTTC CATTAGAGGG TTCCGTCGCT	1740
	GTGGCTGGTG CTGTGGTCCA ATGGCTACGT GATAATTAC GATTGATCGA TAAATCAGAG	1800
35	GATGTCGGAC CGATTGCATC TACGGTCCCT GATTCTGGTG GCGTAGTTT CGTCCCCGCA	1860
	TTTAGTGGCC TATTGCTCC CTATTGGAC CCAGATGCCA GAGCCACCAT AATGGGGATG	1920
40	TCTCAATTCA CTACTGCCTC CCACATGCC AGAGCTGCCG TGGAAGGTGT TTGCTTCAA	1980
	GCCAGGGCTA TCTTGAAGGC AATGAGTTCT GACCGTTCG GTGAAGGTTC CAAAGACAGG	2040
	GACTTTTAG AGGAAATTTC CGACGTCACA TATGAAAAGT CGCCCTGTC GGTTCTGGCA	2100
45	GTGGATGGCG GGATGTCGAG GTCTAATGAA GTCATGCAA TTCAAGCCGA TATCCTAGGT	2160
	CCCTGTGTCA AAGTCAGAAC GTCTCCGACA GCGGAATGTA CCGCATTGGG GGCAGCCATT	2220
	GCAGCCAATA TGGCTTCAA GGATGTGAAC GAGCGCCAT TATGGAAGGA CCTACACGAT	2280
50	GTAAAGAAAT GGGTCTTTA CAATGGAATG GAGAAAAACG AACAAATATC ACCAGAGGCT	2340
	CATCCAAACC TTAAGATATT CAGAAGTGAA TCCGACGATG CTGAAAGGAG AAAGCATTGG	2400
55	AAGTATTGGG AAGTTGCCGT GGAAAGATCC AAAGGTTGGC TGAAGGACAT AGAAGGTGAA	2460

CACGAACAGG TTCTAGAAAA CTTCCAATAA CAACATAAAAT AATTTCTATT AACAAATGTAA 2520

5 (2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 391 amino acids
- (B) TYPE: amino acid
- 10 (C) STRANDEDNESS: unknown
- (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: protein

15 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

20

25

30

35

40

45

50

55

EP 1 034 278 B1

Met Ser Ala Ala Ala Asp Arg Leu Asn Leu Thr Ser Gly His Leu Asn
1 5 10 15

5 Ala Gly Arg Lys Arg Ser Ser Ser Val Ser Leu Lys Ala Ala Glu
20 25 30

Lys Pro Phe Lys Val Thr Val Ile Gly Ser Gly Asn Trp Gly Thr Thr
35 40 45

10 Ile Ala Lys Val Val Ala Glu Asn Cys Lys Gly Tyr Pro Glu Val Phe
50 55 60

15 Ala Pro Ile Val Gln Met Trp Val Phe Glu Glu Ile Asn Gly Glu
65 70 75 80

Lys Leu Thr Glu Ile Ile Asn Thr Arg His Gln Asn Val Lys Tyr Leu
85 90 95

20 Pro Gly Ile Thr Leu Pro Asp Asn Leu Val Ala Asn Pro Asp Leu Ile
100 105 110

Asp Ser Val Lys Asp Val Asp Ile Ile Val Phe Asn Ile Pro His Gln
115 120 125

25 Phe Leu Pro Arg Ile Cys Ser Gln Leu Lys Gly His Val Asp Ser His
130 135 140

30 Val Arg Ala Ile Ser Cys Leu Lys Gly Phe Glu Val Gly Ala Lys Gly
145 150 155 160

Val Gln Leu Leu Ser Ser Tyr Ile Thr Glu Glu Leu Gly Ile Gln Cys
165 170 175

35 Gly Ala Leu Ser Gly Ala Asn Ile Ala Thr Glu Val Ala Gln Glu His
180 185 190

Trp Ser Glu Thr Thr Val Ala Tyr His Ile Pro Lys Asp Phe Arg Gly
195 200 205

40 Glu Gly Lys Asp Val Asp His Lys Val Leu Lys Ala Leu Phe His Arg
210 215 220

Pro Tyr Phe His Val Ser Val Ile Glu Asp Val Ala Gly Ile Ser Ile
225 230 235 240

45

50

55

Cys Gly Ala Leu Lys Asn Val Val Ala Leu Gly Cys Gly Phe Val Glu
 245 250 255

Gly Leu Gly Trp Gly Asn Asn Ala Ser Ala Ala Ile Gln Arg Val Gly
 260 265 270

Leu Gly Glu Ile Ile Arg Phe Gly Gln Met Phe Phe Pro Glu Ser Arg
 275 280 285

Glu Glu Thr Tyr Tyr Gln Glu Ser Ala Gly Val Ala Asp Leu Ile Thr
 290 295 300

Thr Cys Ala Gly Gly Arg Asn Val Lys Val Ala Arg Leu Met Ala Thr
 305 310 315 320

Ser Gly Lys Asp Ala Trp Glu Cys Glu Lys Glu Leu Leu Asn Gly Gln
 325 330 335

Ser Ala Gln Gly Leu Ile Thr Cys Lys Glu Val His Glu Trp Leu Glu
 340 345 350

Thr Cys Gly Ser Val Glu Asp Phe Pro Leu Phe Glu Ala Val Tyr Gln
 355 360 365

Ile Val Tyr Asn Asn Tyr Pro Met Lys Asn Leu Pro Asp Met Ile Glu
 370 375 380

Glu Leu Asp Leu His Glu Asp
 385 390

(2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 384 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: unknown
- (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

EP 1 034 278 B1

Met Thr Ala His Thr Asn Ile Lys Gln His Lys His Cys His Glu Asp
1 5 10 15

5 His Pro Ile Arg Arg Ser Asp Ser Ala Val Ser Ile Val His Leu Lys
20 25 30

Arg Ala Pro Phe Lys Val Thr Val Ile Gly Ser Gly Asn Trp Gly Thr
35 40 45

10 Thr Ile Ala Lys Val Ile Ala Glu Asn Thr Glu Leu His Ser His Ile
50 55 60

15 Phe Glu Pro Glu Val Arg Met Trp Val Phe Asp Glu Lys Ile Gly Asp
65 70 75 80

20

25

30

35

40

45

50

55

EP 1 034 278 B1

	Glu	Asn	Leu	Thr	Asp	Ile	Ile	Asn	Thr	Arg	Gln	Asn	Val	Lys	Tyr		
														90	95		
5	Leu	Pro	Asn	Ile	Asp	Leu	Pro	His	Asn	Leu	Val	Ala	Asp	Pro	Asp	Leu	
														100	105	110	
10	Leu	His	Ser	Ile	Lys	Gly	Ala	Asp	Ile	Leu	Val	Phe	Asn	Ile	Pro	His	
														115	120	125	
15	Gln	Phe	Leu	Pro	Asn	Ile	Val	Lys	Gln	Leu	Gln	Gly	His	Val	Ala	Pro	
														130	135	140	
20	His	Val	Arg	Ala	Ile	Ser	Cys	Leu	Lys	Gly	Phe	Glu	Leu	Gly	Ser	Lys	
														145	150	155	160
25	Gly	Val	Gln	Leu	Leu	Ser	Ser	Tyr	Val	Thr	Asp	Glu	Leu	Gly	Ile	Gln	
														165	170	175	
30	Cys	Gly	Ala	Leu	Ser	Gly	Ala	Asn	Leu	Ala	Pro	Glu	Val	Ala	Lys	Glu	
														180	185	190	
35	His	Trp	Ser	Glu	Thr	Thr	Val	Ala	Tyr	Gln	Leu	Pro	Lys	Asp	Tyr	Gln	
														195	200	205	
40	Gly	Asp	Gly	Lys	Asp	Val	Asp	His	Lys	Ile	Leu	Lys	Leu	Leu	Phe	His	
														210	215	220	
45	Arg	Pro	Tyr	Phe	His	Val	Asn	Val	Ile	Asp	Asp	Val	Ala	Gly	Ile	Ser	
														225	230	235	240
50	Ile	Ala	Gly	Ala	Leu	Lys	Asn	Val	Val	Ala	Leu	Ala	Cys	Gly	Phe	Val	
														245	250	255	
55	Glu	Gly	Met	Gly	Trp	Gly	Asn	Asn	Ala	Ser	Ala	Ala	Ile	Gln	Arg	Leu	
														260	265	270	
60	Gly	Leu	Gly	Glu	Ile	Ile	Lys	Phe	Gly	Arg	Met	Phe	Phe	Pro	Glu	Ser	
														275	280	285	
65	Lys	Val	Glu	Thr	Tyr	Tyr	Gln	Glu	Ser	Ala	Gly	Val	Ala	Asp	Leu	Ile	
														290	295	300	
70	Thr	Thr	Cys	Ser	Gly	Gly	Arg	Asn	Val	Lys	Val	Ala	Thr	Tyr	Met	Ala	
														305	310	315	320
75	Lys	Thr	Gly	Lys	Ser	Ala	Leu	Glu	Ala	Glu	Lys	Glu	Leu	Leu	Asn	Gly	
														325	330	335	
80	Gln	Ser	Ala	Gln	Gly	Ile	Ile	Thr	Cys	Arg	Glu	Val	His	Glu	Trp	Leu	
														340	345	350	
85	Gln	Thr	Cys	Glu	Leu	Thr	Gln	Glu	Phe	Pro	Ile	Ile	Arg	Gly	Ser	Leu	
														355	360	365	
90	Pro	Asp	Ser	Leu	Gln	Gln	Arg	Pro	His	Gly	Arg	Pro	Thr	Gly	Asp	Asp	
														370	375	380	

(2) INFORMATION FOR SEQ ID NO:9:

(i) SEQUENCE CHARACTERISTICS:

5 (A) LENGTH: 614 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: unknown
 (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: protein

10 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

```

Met Thr Arg Ala Thr Trp Cys Asn Ser Pro Pro Pro Pro Leu His Arg Gln
 1           5           10          15

15 Val Ser Arg Arg Asp Leu Leu Asp Arg Leu Asp Lys Thr His Gln Phe
 20           25           30

Asp Val Leu Ile Ile Gly Gly Ala Thr Gly Thr Gly Cys Ala Leu
 20           35           40           45

Asp Ala Ala Thr Arg Gly Leu Asn Val Ala Leu Val Glu Lys Gly Asp
 25           50           55           60

Phe Ala Ser Gly Thr Ser Ser Lys Ser Thr Lys Met Ile His Gly Gly
 25           65           70           75           80

Val Arg Tyr Leu Glu Lys Ala Phe Trp Glu Phe Ser Lys Ala Gln Leu
 30           85           90           95

Asp Leu Val Ile Glu Ala Leu Asn Glu Arg Lys His Leu Ile Asn Thr
 35           100          105          110

Ala Pro His Leu Cys Thr Val Leu Pro Ile Leu Ile Pro Ile Tyr Ser
 35           115          120          125

Thr Trp Gln Val Pro Tyr Ile Tyr Met Gly Cys Lys Phe Tyr Asp Phe
 40           130          135          140

Phe Gly Gly Ser Gln Asn Leu Lys Lys Ser Tyr Leu Leu Ser Lys Ser
 45           145          150          155          160

Ala Thr Val Glu Lys Ala Pro Met Leu Thr Thr Asp Asn Leu Lys Ala
 50           165          170          175

Ser Leu Val Tyr His Asp Gly Ser Phe Asn Asp Ser Arg Leu Asn Ala
 55           180          185          190

Thr Leu Ala Ile Thr Gly Val Glu Asn Gly Ala Thr Val Leu Ile Tyr
 60           195          200          205

Val Glu Val Gln Lys Leu Ile Lys Asp Pro Thr Ser Gly Lys Val Ile
 65           210          215          220

Gly Ala Glu Ala Arg Asp Val Glu Thr Asn Glu Leu Val Arg Ile Asn
 70           225          230          235          240

```

EP 1 034 278 B1

Ala Lys Cys Val Val Asn Ala Thr Gly Pro Tyr Ser Asp Ala Ile Leu
245 250 255

5 Gln Met Asp Arg Asn Pro Ser Gly Leu Pro Asp Ser Pro Leu Asn Asp
260 265 270

Asn Ser Lys Ile Lys Ser Thr Phe Asn Gln Ile Ser Val Met Asp Pro
275 280 285

10 Lys Met Val Ile Pro Ser Ile Gly Val His Ile Val Leu Pro Ser Phe
290 295 300

15 Tyr Ser Pro Lys Asp Met Gly Leu Leu Asp Val Arg Thr Ser Asp Gly
305 310 315 320

Arg Val Met Phe Phe Leu Pro Trp Gln Gly Lys Val Leu Ala Gly Thr
325 330 335

20 Thr Asp Ile Pro Leu Lys Gln Val Pro Glu Asn Pro Met Pro Thr Glu
340 345 350

Ala Asp Ile Gln Asp Ile Leu Lys Glu Leu Gln His Tyr Ile Glu Phe
355 360 365

25 Pro Val Lys Arg Glu Asp Val Leu Ser Ala Trp Ala Gly Val Arg Pro
370 375 380

Leu Val Arg Asp Pro Arg Thr Ile Pro Ala Asp Gly Lys Lys Gly Ser
385 390 395 400

30 Ala Thr Gln Gly Val Val Arg Ser His Phe Leu Phe Thr Ser Asp Asn
405 410 415

Gly Leu Ile Thr Ile Ala Gly Gly Lys Trp Thr Thr Tyr Arg Gln Met
420 425 430

35 Ala Glu Glu Thr Val Asp Lys Val Val Glu Val Gly Phe His Asn
435 440 445

40 Leu Lys Pro Cys His Thr Arg Asp Ile Lys Leu Ala Gly Ala Glu Glu
450 455 460

Trp Thr Gln Asn Tyr Val Ala Leu Leu Ala Gln Asn Tyr His Leu Ser
465 470 475 480

45 Ser Lys Met Ser Asn Tyr Leu Val Gln Asn Tyr Gly Thr Arg Ser Ser
485 490 495

Ile Ile Cys Glu Phe Phe Lys Glu Ser Met Glu Asn Lys Leu Pro Leu
500 505 510

50 Ser Leu Ala Asp Lys Glu Asn Asn Val Ile Tyr Ser Ser Glu Glu Asn
515 520 525

55 Asn Leu Val Asn Phe Asp Thr Phe Arg Tyr Pro Phe Thr Ile Gly Glu
530 535 540

Leu Lys Tyr Ser Met Gln Tyr Glu Tyr Cys Arg Thr Pro Leu Asp Phe
545 550 555 560

5 Leu Leu Arg Arg Thr Arg Phe Ala Phe Leu Asp Ala Lys Glu Ala Leu
565 570 575

10 Asn Ala Val His Ala Thr Val Lys Val Met Gly Asp Glu Phe Asn Trp
580 585 590

15 Ser Glu Lys Lys Arg Gln Trp Glu Leu Glu Lys Thr Val Asn Phe Ile
595 600 605

Gln Gly Arg Phe Gly Val
610

(2) INFORMATION FOR SEQ ID NO:10:

20 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 339 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: unknown
25 (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: protein

30 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

35

40

45

50

55

EP 1 034 278 B1

Met Asn Gln Arg Asn Ala Ser Met Thr Val Ile Gly Ala Gly Ser Tyr
1 5 10 15

5 Gly Thr Ala Leu Ala Ile Thr Leu Ala Arg Asn Gly His Glu Val Val
20 25 30

Leu Trp Gly His Asp Pro Glu His Ile Ala Thr Leu Glu Arg Asp Arg
35 40 45

10 Cys Asn Ala Ala Phe Leu Pro Asp Val Pro Phe Pro Asp Thr Leu His
50 55 60

15 Leu Glu Ser Asp Leu Ala Thr Ala Leu Ala Ala Ser Arg Asn Ile Leu
65 70 75 80

Val Val Val Pro Ser His Val Phe Gly Glu Val Leu Arg Gin Ile Lys
85 90 95

20 Pro Leu Met Arg Pro Asp Ala Arg Leu Val Trp Ala Thr Lys Gly Leu
100 105 110

Glu Ala Glu Thr Gly Arg Leu Leu Gln Asp Val Ala Arg Glu Ala Leu
115 120 125

25 Gly Asp Gln Ile Pro Leu Ala Val Ile Ser Gly Pro Thr Phe Ala Lys
130 135 140

30 Glu Leu Ala Ala Gly Leu Pro Thr Ala Ile Ser Leu Ala Ser Thr Asp
145 150 155 160

35

40

45

50

55

Gln Thr Phe Ala Asp Asp Leu Gln Gln Leu Leu His Cys Gly Lys Ser
 165 170 175
 5 Phe Arg Val Tyr Ser Asn Pro Asp Phe Ile Gly Val Gln Leu Gly Gly
 180 185 190
 Ala Val Lys Asn Val Ile Ala Ile Gly Ala Gly Met Ser Asp Gly Ile
 195 200 205
 10 Gly Phe Gly Ala Asn Ala Arg Thr Ala Leu Ile Thr Arg Gly Leu Ala
 210 215 220
 15 Glu Met Ser Arg Leu Gly Ala Ala Leu Gly Ala Asp Pro Ala Thr Phe
 225 230 235 240
 Met Gly Met Ala Gly Leu Gly Asp Leu Val Leu Thr Cys Thr Asp Asn
 245 250 255
 20 Gln Ser Arg Asn Arg Arg Phe Gly Met Met Leu Gly Gln Gly Met Asp
 260 265 270
 Val Gln Ser Ala Gln Glu Lys Ile Gly Gln Val Val Glu Gly Tyr Arg
 275 280 285
 25 Asn Thr Lys Glu Val Arg Glu Leu Ala His Arg Phe Gly Val Glu Met
 290 295 300
 Pro Ile Thr Glu Glu Ile Tyr Gln Val Leu Tyr Cys Gly Lys Asn Ala
 305 310 315 320
 30 Arg Glu Ala Ala Leu Thr Leu Leu Gly Arg Ala Arg Lys Asp Glu Arg
 325 330 335
 35 Ser Ser His

(2) INFORMATION FOR SEQ ID NO:11:

(i) SEQUENCE CHARACTERISTICS:

40 (A) LENGTH: 501 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: unknown
 (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

50

55

EP 1 034 278 B1

Met Glu Thr Lys Asp Leu Ile Val Ile Gly Gly Gly Ile Asn Gly Ala
1 5 10 15

5 Gly Ile Ala Ala Asp Ala Ala Gly Arg Gly Leu Ser Val Leu Met Leu
20 25 30

Glu Ala Gln Asp Leu Ala Cys Ala Thr Ser Ser Ala Ser Ser Lys Leu
35 40 45

10 Ile His Gly Leu Arg Tyr Leu Glu His Tyr Glu Phe Arg Leu Val
50 55 60

15

20

25

30

35

40

45

50

55

EP 1 034 278 B1

5	Ser	Glu	Ala	Leu	Ala	Glu	Arg	Glu	Val	Leu	Leu	Lys	Met	Ala	Pro	His
	65					70				75						80
10	Ile	Ala	Phe	Pro	Met	Arg	Phe	Arg	Leu	Pro	His	Arg	Pro	His	Leu	Arg
					85					90					95	
15	Pro	Ala	Trp	Met	Ile	Arg	Ile	Gly	Leu	Phe	Met	Tyr	Asp	His	Leu	Gly
					100				105					110		
20	Lys	Arg	Thr	Ser	Leu	Pro	Gly	Ser	Thr	Gly	Leu	Arg	Phe	Gly	Ala	Asn
					115				120				125			
25	Ser	Val	Leu	Lys	Pro	Glu	Ile	Lys	Arg	Gly	Phe	Glu	Tyr	Ser	Asp	Cys
					130				135			140				
30	Trp	Val	Asp	Asp	Ala	Arg	Leu	Val	Leu	Ala	Asn	Ala	Gln	Met	Val	Val
					145			150			155			160		
35	Arg	Lys	Gly	Gly	Glu	Val	Leu	Thr	Arg	Thr	Arg	Ala	Thr	Ser	Ala	Arg
					165				170				175			
40	Arg	Glu	Asn	Gly	Leu	Trp	Ile	Val	Glu	Ala	Glu	Asp	Ile	Asp	Thr	Gly
					180				185			190				
45	Lys	Lys	Tyr	Ser	Trp	Gln	Ala	Arg	Gly	Leu	Val	Asn	Ala	Thr	Gly	Pro
					195				200			205				
50	Trp	Val	Lys	Gln	Phe	Phe	Asp	Asp	Gly	Met	His	Leu	Pro	Ser	Pro	Tyr
					210			215			220					
55	Gly	Ile	Arg	Leu	Ile	Lys	Gly	Ser	His	Ile	Val	Val	Pro	Arg	Val	His
					225			230			235			240		
60	Thr	Gln	Lys	Gln	Ala	Tyr	Ile	Leu	Gln	Asn	Glu	Asp	Lys	Arg	Ile	Val
						245				250			255			
65	Phe	Val	Ile	Pro	Trp	Met	Asp	Glu	Phe	Ser	Ile	Ile	Gly	Thr	Thr	Asp
						260			265			270				
70	Val	Glu	Tyr	Lys	Gly	Asp	Pro	Lys	Ala	Val	Lys	Ile	Glu	Glu	Ser	Glu
						275			280			285				
75	Ile	Asn	Tyr	Leu	Leu	Asn	Val	Tyr	Asn	Thr	His	Phe	Lys	Lys	Gln	Leu
						290			295			300				
80	Ser	Arg	Asp	Asp	Ile	Val	Trp	Thr	Tyr	Ser	Gly	Val	Arg	Pro	Leu	Cys
						305			310			315			320	
85	Asp	Asp	Glu	Ser	Asp	Ser	Pro	Gln	Ala	Ile	Thr	Arg	Asp	Tyr	Thr	Leu
						325				330			335			
90	Asp	Ile	His	Asp	Glu	Asn	Gly	Lys	Ala	Pro	Leu	Leu	Ser	Val	Phe	Gly
						340			345			350				
95	Gly	Lys	Leu	Thr	Thr	Tyr	Arg	Lys	Leu	Ala	Glu	His	Ala	Leu	Glu	Lys
						355			360			365				

Leu Thr Pro Tyr Tyr Gln Gly Ile Gly Pro Ala Trp Thr Lys Glu Ser
370 375 380

5 Val Leu Pro Gly Gly Ala Ile Glu Gly Asp Arg Asp Asp Tyr Ala Ala
385 390 395 400

Arg Leu Arg Arg Arg Tyr Pro Phe Leu Thr Glu Ser Leu Ala Arg His
405 410 415

10 Tyr Ala Arg Thr Tyr Gly Ser Asn Ser Glu Leu Leu Leu Gly Asn Ala
420 425 430

Gly Thr Val Ser Asp Leu Gly Glu Asp Phe Gly His Glu Phe Tyr Glu
15 435 440 445

Ala Glu Leu Lys Tyr Leu Val Asp His Glu Trp Val Arg Arg Ala Asp
450 455 460

20 Asp Ala Leu Trp Arg Arg Thr Lys Gln Gly Met Trp Leu Asn Ala Asp
465 470 475 480

Gln Gln Ser Arg Val Ser Gln Trp Leu Val Glu Tyr Thr Gln Gln Arg
485 490 495

25 Leu Ser Leu Ala Ser
500

(2) INFORMATION FOR SEQ ID NO:12:

30 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 542 amino acids
(B) TYPE: amino acid
35 (C) STRANDEDNESS: unknown
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: protein

40 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

45

50

55

EP 1 034 278 B1

Met Lys Thr Arg Asp Ser Gln Ser Ser Asp Val Ile Ile Ile Gly Gly
1 5 10 15

5 Gly Ala Thr Gly Ala Gly Ile Ala Arg Asp Cys Ala Leu Arg Gly Leu
20 25 30

10 Arg Val Ile Leu Val Glu Arg His Asp Ile Ala Thr Gly Ala Thr Gly
35 40 45

15 Arg Asn His Gly Leu Leu His Ser Gly Ala Arg Tyr Ala Val Thr Asp
50 55 60

20 Ala Glu Ser Ala Arg Glu Cys Ile Ser Glu Asn Gln Ile Leu Lys Arg
65 70 75 80

Ile Ala Arg His Cys Val Glu Pro Thr Asn Gly Leu Phe Ile Thr Leu
85 90 95

25

30

35

40

45

50

55

EP 1 034 278 B1

Pro Glu Asp Asp Leu Ser Phe Gln Ala Thr Phe Ile Arg Ala Cys Glu
100 105 110

5 Glu Ala Gly Ile Ser Ala Glu Ala Ile Asp Pro Gln Gln Ala Arg Ile
115 120 125

Ile Glu Pro Ala Val Asn Pro Ala Leu Ile Gly Ala Val Lys Val Pro
130 135 140

10 Asp Gly Thr Val Asp Pro Phe Arg Leu Thr Ala Ala Asn Met Leu Asp
145 150 155 160

Ala Lys Glu His Gly Ala Val Ile Leu Thr Ala His Glu Val Thr Gly
15 165 170 175

Leu Ile Arg Glu Gly Ala Thr Val Cys Gly Val Arg Val Arg Asn His
180 185 190

Leu Thr Gly Glu Thr Gln Ala Leu His Ala Pro Val Val Val Asn Ala
20 195 200 205

Ala Gly Ile Trp Gly Gln His Ile Ala Glu Tyr Ala Asp Leu Arg Ile
210 215 220

25 Arg Met Phe Pro Ala Lys Gly Ser Leu Leu Ile Met Asp His Arg Ile
225 230 235 240

Asn Gln His Val Ile Asn Arg Cys Arg Lys Pro Ser Asp Ala Asp Ile
245 250 255

30 Leu Val Pro Gly Asp Thr Ile Ser Leu Ile Gly Thr Thr Ser Leu Arg
260 265 270

Ile Asp Tyr Asn Glu Ile Asp Asp Asn Arg Val Thr Ala Glu Glu Val
35 275 280 285

Asp Ile Leu Leu Arg Glu Gly Glu Lys Leu Ala Pro Val Met Ala Lys
290 295 300

40 Thr Arg Ile Leu Arg Ala Tyr Ser Gly Val Arg Pro Leu Val Ala Ser
305 310 315 320

Asp Asp Asp Pro Ser Gly Arg Asn Leu Ser Arg Gly Ile Val Leu Leu
325 330 335

45 Asp His Ala Glu Arg Asp Gly Leu Asp Gly Phe Ile Thr Ile Thr Gly
340 345 350

Gly Lys Leu Met Thr Tyr Arg Leu Met Ala Glu Trp Ala Thr Asp Ala
50 355 360 365

Val Cys Arg Lys Leu Gly Asn Thr Arg Pro Cys Thr Thr Ala Asp Leu
370 375 380

Ala Leu Pro Gly Ser Gln Glu Pro Ala Glu Val Thr Leu Arg Lys Val
55 385 390 395 400

Ile Ser Leu Pro Ala Pro Leu Arg Gly Ser Ala Val Tyr Arg His Gly
405 410 415

5 Asp Arg Thr Pro Ala Trp Leu Ser Glu Gly Arg Leu His Arg Ser Leu
420 425 430

Val Cys Glu Cys Glu Ala Val Thr Ala Gly Glu Val Gln Tyr Ala Val
435 440 445

10 Glu Asn Leu Asn Val Asn Ser Leu Leu Asp Leu Arg Arg Arg Thr Arg
450 455 460

15 Val Gly Met Gly Thr Cys Gln Gly Glu Leu Cys Ala Cys Arg Ala Ala
465 470 475 480

Gly Leu Leu Gln Arg Phe Asn Val Thr Thr Ser Ala Gln Ser Ile Glu
485 490 495

20 Gln Leu Ser Thr Phe Leu Asn Glu Arg Trp Lys Gly Val Gln Pro Ile
500 505 510

Ala Trp Gly Asp Ala Leu Arg Glu Ser Glu Phe Thr Arg Trp Val Tyr
515 520 525

25 Gln Gly Leu Cys Gly Leu Glu Lys Glu Gln Lys Asp Ala Leu
530 535 540

(2) INFORMATION FOR SEQ ID NO:13:

30 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 250 amino acids
(B) TYPE: amino acid
35 (C) STRANDEDNESS: unknown
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: protein

40 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

45

50

55

Met	Gly	Leu	Thr	Thr	Lys	Pro	Leu	Ser	Leu	Lys	Val	Asn	Ala	Ala	Leu	
1									10					15		
5																
	Phe	Asp	Val	Asp	Gly	Thr	Ile	Ile	Ser	Gln	Pro	Ala	Ile	Ala	Ala	
									25					30		
10																
	Phe	Trp	Arg	Asp	Phe	Gly	Lys	Asp	Lys	Pro	Tyr	Phe	Asp	Ala	Glu	His
							35		40				45			
15																
	Val	Ile	Gln	Val	Ser	His	Gly	Trp	Arg	Thr	Phe	Asp	Ala	Ile	Ala	Lys
													50	60		
20																
	Phe	Ala	Pro	Asp	Phe	Ala	Asn	Glu	Glu	Tyr	Val	Asn	Lys	Leu	Glu	Ala
							65		70			75		80		
25																
	Glu	Ile	Pro	Val	Lys	Tyr	Gly	Glu	Lys	Ser	Ile	Glu	Val	Pro	Gly	Ala
							85		90			95				
30																
	Val	Lys	Leu	Cys	Asn	Ala	Leu	Asn	Ala	Leu	Pro	Lys	Glu	Lys	Trp	Ala
							100		105			110				
35																
	Val	Ala	Thr	Ser	Gly	Thr	Arg	Asp	Met	Ala	Gln	Lys	Trp	Phe	Glu	His
							115		120			125				
40																
	Leu	Gly	Ile	Arg	Arg	Pro	Lys	Tyr	Phe	Ile	Thr	Ala	Asn	Asp	Val	Lys
							130		135			140				
45																
	Gln	Gly	Lys	Pro	His	Pro	Glu	Pro	Tyr	Leu	Lys	Gly	Arg	Asn	Gly	Leu
							145		150			155		160		
50																
	Gly	Tyr	Pro	Ile	Asn	Glu	Gln	Asp	Pro	Ser	Lys	Ser	Lys	Val	Val	Val
							165		170			175				
55																
	Phe	Glu	Asp	Ala	Pro	Ala	Gly	Ile	Ala	Ala	Gly	Lys	Ala	Ala	Gly	Cys
							180		185			190				
60																
	Lys	Ile	Ile	Gly	Ile	Ala	Thr	Thr	Phe	Asp	Leu	Asp	Phe	Leu	Lys	Glu
							195		200			205				
65																
	Lys	Gly	Cys	Asp	Ile	Ile	Val	Lys	Asn	His	Glu	Ser	Ile	Arg	Val	Gly
							210		215			220				
70																
	Gly	Tyr	Asn	Ala	Glu	Thr	Asp	Glu	Val	Glu	Phe	Ile	Phe	Asp	Asp	Tyr
							225		230			235		240		
75																
	Leu	Tyr	Ala	Lys	Asp	Asp	Leu	Leu	Lys	Trp						
							245		250							

(2) INFORMATION FOR SEQ ID NO:14:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 271 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: unknown

(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: protein

5 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

Met Lys Arg Phe Asn Val Leu Lys Tyr Ile Arg Thr Thr Lys Ala Asn
1 5 10 15

10 Ile Gln Thr Ile Ala Met Pro Leu Thr Thr Lys Pro Leu Ser Leu Lys
20 25 30

15 Ile Asn Ala Ala Leu Phe Asp Val Asp Gly Thr Ile Ile Ile Ser Gln
35 40 45

Pro Ala Ile Ala Ala Phe Trp Arg Asp Phe Gly Lys Asp Lys Pro Tyr
50 55 60

20 Phe Asp Ala Glu His Val Ile His Ile Ser His Gly Trp Arg Thr Tyr
65 70 75 80

25

30

35

40

45

50

55

Asp Ala Ile Ala Lys Phe Ala Pro Asp Phe Ala Asp Glu Glu Tyr Val
 85 90 95
 5 Asn Lys Leu Glu Gly Glu Ile Pro Glu Lys Tyr Gly Glu His Ser Ile
 100 105 110
 Glu Val Pro Gly Ala Val Lys Leu Cys Asn Ala Leu Asn Ala Leu Pro
 115 120 125
 10 Lys Glu Lys Trp Ala Val Ala Thr Ser Gly Thr Arg Asp Met Ala Lys
 130 135 140
 Lys Trp Phe Asp Ile Leu Lys Ile Lys Arg Pro Glu Tyr Phe Ile Thr
 145 150 155 160
 15 Ala Asn Asp Val Lys Gln Gly Lys Pro His Pro Glu Pro Tyr Leu Lys
 165 170 175
 Gly Arg Asn Gly Leu Gly Phe Pro Ile Asn Glu Gln Asp Pro Ser Lys
 180 185 190
 Ser Lys Val Val Val Phe Glu Asp Ala Pro Ala Gly Ile Ala Ala Gly
 195 200 205
 25 Lys Ala Ala Gly Cys Lys Ile Val Gly Ile Ala Thr Thr Phe Asp Leu
 210 215 220
 Asp Phe Leu Lys Glu Lys Gly Cys Asp Ile Ile Val Lys Asn His Glu
 225 230 235 240
 30 Ser Ile Arg Val Gly Glu Tyr Asn Ala Glu Thr Asp Glu Val Glu Leu
 245 250 255
 Ile Phe Asp Asp Tyr Leu Tyr Ala Lys Asp Asp Leu Leu Lys Trp
 35 260 265 270

(2) INFORMATION FOR SEQ ID NO:15:

40 (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 709 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: unknown
- (D) TOPOLOGY: unknown

45 (ii) MOLECULE TYPE: protein

50 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

EP 1 034 278 B1

Met Phe Pro Ser Leu Phe Arg Leu Val Val Phe Ser Lys Arg Tyr Ile
1 5 10 15

5 Phe Arg Ser Ser Gln Arg Leu Tyr Thr Ser Leu Lys Gln Glu Gln Ser
20 25 30

Arg Met Ser Lys Ile Met Glu Asp Leu Arg Ser Asp Tyr Val Pro Leu
35 40 45

10

15

20

25

30

35

40

45

50

55

EP 1 034 278 B1

Ile Ala Ser Ile Asp Val Gly Thr Thr Ser Ser Arg Cys Ile Leu Phe
50 55 60

Asn Arg Trp Gly Gln Asp Val Ser Lys His Gln Ile Glu Tyr Ser Thr
65 70 75 80

Ser Ala Ser Lys Gly Lys Ile Gly Val Ser Gly Leu Arg Arg Pro Ser
85 . 90 95

10 Thr Ala Pro Ala Arg Glu Thr Pro Asn Ala Gly Asp Ile Lys Thr Ser
100 105 110

Gly Lys Pro Ile Phe Ser Ala Glu Gly Tyr Ala Ile Gln Glu Thr Lys
15 115 120 125

Phe Leu Lys Ile Glu Glu Leu Asp Leu Asp Phe His Asn Glu Pro Thr
130 135 140

20 Leu Lys Phe Pro Lys Pro Gly Trp Val Glu Cys His Pro Gln Lys Leu
145 150 155 160

Leu Val Asn Val Val Gln Cys Leu Ala Ser Ser Leu Leu Ser Leu Gln
165 170 175

25 Thr Ile Asn Ser Glu Arg Val Ala Asn Gly Leu Pro Pro Tyr Lys Val
180 185 190

Ile Cys Met Gly Ile Ala Asn Met Arg Glu Thr Thr Ile Leu Trp Ser
30 195 200 205

Arg Arg Thr Gly Lys Pro Ile Val Asn Tyr Gly Ile Val Trp Asn Asp
210 215 220

35 Thr Arg Thr Ile Lys Ile Val Arg Asp Lys Trp Gln Asn Thr Ser Val
225 230 235 240

Asp Arg Gln Leu Gln Leu Arg Gln Lys Thr Gly Leu Pro Leu Leu Ser
245 250 255

40 Thr Tyr Phe Ser Cys Ser Lys Leu Arg Trp Phe Leu Asp Asn Glu Pro
260 265 270

Leu Cys Thr Lys Ala Tyr Glu Glu Asn Asp Leu Met Phe Gly Thr Val
45 275 280 285

Asp Thr Trp Leu Ile Tyr Gln Leu Thr Lys Gln Lys Ala Phe Val Ser
290 295 300

50 Asp Val Thr Asn Ala Ser Arg Thr Gly Phe Met Asn Leu Ser Thr Leu
305 310 315 320

Lys Tyr Asp Asn Glu Leu Leu Glu Phe Trp Gly Ile Asp Lys Asn Leu
55 325 330 335

Ile His Met Pro Glu Ile Val Ser Ser Gln Tyr Tyr Gly Asp Phe
340 345 350

EP 1034 278 B1

Gly Ile Pro Asp Trp Ile Met Glu Lys Leu His Asp Ser Pro Lys Thr
355 360 365

5 Val Leu Arg Asp Leu Val Lys Arg Asn Leu Pro Ile Gln Gly Cys Leu
370 375 380

Gly Asp Gln Ser Ala Ser Met Val Gly Gln Leu Ala Tyr Lys Pro Gly
385 390 395 400

10 Ala Ala Lys Cys Thr Tyr Gly Thr Gly Cys Phe Leu Leu Tyr Asn Thr
405 410 415

Gly Thr Lys Lys Leu Ile Ser Gln His Gly Ala Leu Thr Thr Leu Ala
15 420 425 430

Phe Trp Phe Pro His Leu Gln Glu Tyr Gly Gly Gln Lys Pro Glu Leu
435 440 445

20 Ser Lys Pro His Phe Ala Leu Glu Gly Ser Val Ala Val Ala Gly Ala
450 455 460

Val Val Gln Trp Leu Arg Asp Asn Leu Arg Leu Ile Asp Lys Ser Glu
465 470 475 480

25 Asp Val Gly Pro Ile Ala Ser Thr Val Pro Asp Ser Gly Gly Val Val
485 490 495

Phe Val Pro Ala Phe Ser Gly Leu Phe Ala Pro Tyr Trp Asp Pro Asp
30 500 505 510

Ala Arg Ala Thr Ile Met Gly Met Ser Gln Phe Thr Thr Ala Ser His
515 520 525

Ile Ala Arg Ala Ala Val Glu Gly Val Cys Phe Gln Ala Arg Ala Ile
35 530 535 540

Leu Lys Ala Met Ser Ser Asp Ala Phe Gly Glu Gly Ser Lys Asp Arg
545 550 555 560

40 Asp Phe Leu Glu Glu Ile Ser Asp Val Thr Tyr Glu Lys Ser Pro Leu
565 570 575

Ser Val Leu Ala Val Asp Gly Gly Met Ser Arg Ser Asn Glu Val Met
580 585 590

45 Gln Ile Gln Ala Asp Ile Leu Gly Pro Cys Val Lys Val Arg Arg Ser
595 600 605

Pro Thr Ala Glu Cys Thr Ala Leu Gly Ala Ala Ile Ala Ala Asn Met
50 610 615 620

Ala Phe Lys Asp Val Asn Glu Arg Pro Leu Trp Lys Asp Leu His Asp
625 630 635 640

55 Val Lys Lys Trp Val Phe Tyr Asn Gly Met Glu Lys Asn Glu Gln Ile
645 650 655

Ser Pro Glu Ala His Pro Asn Leu Lys Ile Phe Arg Ser Glu Ser Asp
660 665 670
5 Asp Ala Glu Arg Arg Lys His Trp Lys Tyr Trp Glu Val Ala Val Glu
675 680 685
Arg Ser Lys Gly Trp Leu Lys Asp Ile Glu Gly Glu His Glu Gln Val
690 695 700
10 Leu Glu Asn Phe Gln
705

15 (2) INFORMATION FOR SEQ ID NO:16:

(i) SEQUENCE CHARACTERISTICS:

20 (A) LENGTH: 51 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

25 (ii) MOLECULE TYPE: DNA (genomic)

25 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

30 GCGCGGATCC AGGAGTCTAG AATTATGGGA TTGACTACTA AACCTCTATC T 51

30 (2) INFORMATION FOR SEQ ID NO:17:

(i) SEQUENCE CHARACTERISTICS:

35 (A) LENGTH: 36 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

40 (ii) MOLECULE TYPE: DNA (genomic)

40 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

45 GATACGCCCG GGT TACCATT TCAACAGATC GTCCTT 36

45 (2) INFORMATION FOR SEQ ID NO:18:

(i) SEQUENCE CHARACTERISTICS:

50 (A) LENGTH: 34 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

55 (ii) MOLECULE TYPE: DNA (genomic)

55 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

TTGATAATAT AACCATGGCT GCTGCTGCTG ATAG

34

5 (2) INFORMATION FOR SEQ ID NO:19:

(i) SEQUENCE CHARACTERISTICS:

10 (A) LENGTH: 39 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

15 (ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

20 GTATGATATG TTATCTTGG A TCCAATAAAT CTAATCTTC

39

(2) INFORMATION FOR SEQ ID NO:20:

25 (i) SEQUENCE CHARACTERISTICS:

30 (A) LENGTH: 24 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

35 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

CATGACTAGT AAGGAGGACA ATTC

24

(2) INFORMATION FOR SEQ ID NO:21:

40 (i) SEQUENCE CHARACTERISTICS:

45 (A) LENGTH: 24 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

50 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

CATGGAATTG TCCTCCTTAC TAGT

24

55 (2) INFORMATION FOR SEQ ID NO:22:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 19 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

5

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:

10

CTAGTAAGGA GGACAATT

19

(2) INFORMATION FOR SEQ ID NO:23:

15

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 19 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

25

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:

CATGGAATTG TCCTCCTTA

19

30

(2) INFORMATION FOR SEQ ID NO:24:

35

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 15 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

40

(ii) MOLECULE TYPE: other nucleic acid

(A) DESCRIPTION: /desc = "PRIMER"

45

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:

50

GATCCAGGAA ACAGA

15

(2) INFORMATION FOR SEQ ID NO:25:

55

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 15 base pairs
(B) TYPE: nucleic acid

(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

5 (ii) MOLECULE TYPE: other nucleic acid

(A) DESCRIPTION: /desc = "PRIMER"

10 (iii) HYPOTHETICAL: NO

15 (iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:

15 CTAGTCTGTT TCCTG

15

(2) INFORMATION FOR SEQ ID NO:26:

20 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 22 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

25 (ii) MOLECULE TYPE: other nucleic acid

(A) DESCRIPTION: /desc = "PRIMER"

30 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:

GCTTTCTGTG CTGCGGCTTT AG

22

35 (2) INFORMATION FOR SEQ ID NO:27:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 23 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

40 (ii) MOLECULE TYPE: other nucleic acid

(A) DESCRIPTION: /desc = "PRIMER"

45 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:

50 TGGTCGAGGA TCCACTTCAC TTT

23

(2) INFORMATION FOR SEQ ID NO:28:

55 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 51 base pairs
(3) TYPE: nucleic acid

(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

5 (ii) MOLECULE TYPE: other nucleic acid

(A) DESCRIPTION: /desc = "PRIMER"

10 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:

AAAGTGAAGT GGATCCTCGA CCAATTGGAT GGTGGCGCAG TAGCAAACAA T

51

(2) INFORMATION FOR SEQ ID NO:29:

15 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 23 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
20 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(A) DESCRIPTION: /desc = "PRIMER"

25 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:

GGATCACCGC CGCAGAAACT ACG

30 23

(2) INFORMATION FOR SEQ ID NO:30:

(i) SEQUENCE CHARACTERISTICS:

35 (A) LENGTH: 25 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

40 (ii) MOLECULE TYPE: other nucleic acid

(A) DESCRIPTION: /desc = "PRIMER"

45 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:30:

CTGTCAGCCG TTAAGTGTTC CTGTG

45 25

(2) INFORMATION FOR SEQ ID NO:31:

50 (i) SEQUENCE CHARACTERISTICS:

55 (A) LENGTH: 23 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(A) DESCRIPTION: /desc = "PRIMER"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:31:

5 CAGTTCAACC TGTTGATAGT ACG

23

(2) INFORMATION FOR SEQ ID NO:32:

10 (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

15 (ii) MOLECULE TYPE: other nucleic acid

20 (A) DESCRIPTION: /desc = "PRIMER"

25 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:32:

ATGAGTCAAA CATCACACCTT

20

(2) INFORMATION FOR SEQ ID NO:33:

30 (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

35 (ii) MOLECULE TYPE: other nucleic acid

(A) DESCRIPTION: /desc = "PRIMER"

40 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:33:

ATGGAGAAAA AAATCACTGG

20

(2) INFORMATION FOR SEQ ID NO:34:

45 (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

50 (ii) MOLECULE TYPE: other nucleic acid

(A) DESCRIPTION: /desc = "PRIMER"

55 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:34:

TTACGCCCG CCCTGCCACT

20

5 (2) INFORMATION FOR SEQ ID NO:35:

(i) SEQUENCE CHARACTERISTICS:

10 (A) LENGTH: 20 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

15 (A) DESCRIPTION: /desc = "PRIMER"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:35:

20 TCAGAGGATG TGCACCTGCA

20

25 (2) INFORMATION FOR SEQ ID NO:36:

(i) SEQUENCE CHARACTERISTICS:

30 (A) LENGTH: 26 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

35 (A) DESCRIPTION: /desc = "PRIMER"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:36:

40 CGAGCATGCC GCATTTGGCA CTACTC

26

(2) INFORMATION FOR SEQ ID NO:37:

(i) SEQUENCE CHARACTERISTICS:

45 (A) LENGTH: 29 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

50 (A) DESCRIPTION: /desc = "PRIMER"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:37:

GCGTCTAGAG TAGGTTATTC CCACTCTTG

29

(2) INFORMATION FOR SEQ ID NO:38:

(i) SEQUENCE CHARACTERISTICS:

5 (A) LENGTH: 26 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

10 (ii) MOLECULE TYPE: other nucleic acid

(A) DESCRIPTION: /desc = "PRIMER"

15 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:38:

GAAGTCGACC GCTGCGCCTT ATCCGG

26

20 (2) INFORMATION FOR SEQ ID NO:39:

(i) SEQUENCE CHARACTERISTICS:

25 (A) LENGTH: 28 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

30 (ii) MOLECULE TYPE: other nucleic acid

(A) DESCRIPTION: /desc = "PRIMER"

35 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:39:

CGCGTCGACG TTTACAATTT CAGGTGGC

28

(2) INFORMATION FOR SEQ ID NO:40:

40 (i) SEQUENCE CHARACTERISTICS:

45 (A) LENGTH: 23 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(A) DESCRIPTION: /desc = "PRIMER"

50 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:40:

GCAGCATGCT GGACTGGTAG TAG

23

55 (2) INFORMATION FOR SEQ ID NO:41:

(i) SEQUENCE CHARACTERISTICS:

5 (A) LENGTH: 27 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

10 (ii) MOLECULE TYPE: other nucleic acid

(A) DESCRIPTION: /desc = "PRIMER"

15 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:41:

CAGTCTAGAG TTATTGGCAA ACCTACC

27

15 (2) INFORMATION FOR SEQ ID NO:42:

(i) SEQUENCE CHARACTERISTICS:

20 (A) LENGTH: 25 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

25 (ii) MOLECULE TYPE: other nucleic acid

(A) DESCRIPTION: /desc = "PRIMER"

30 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:42:

GATGCATGCC CAGGGCGGAG ACGGC

25

35 (2) INFORMATION FOR SEQ ID NO:43:

(i) SEQUENCE CHARACTERISTICS:

40 (A) LENGTH: 29 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

45 (A) DESCRIPTION: /desc = "PRIMER"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:43:

50 CTAACGATTG TTCTCTAGAG AAAATGTCC

29

(2) INFORMATION FOR SEQ ID NO:44:

(i) SEQUENCE CHARACTERISTICS:

55 (A) LENGTH: 30 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

5 (A) DESCRIPTION: /desc = "primer"

(iii) HYPOTHETICAL: NO

10 (iv) ANTI-SENSE: NO

15 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:44:

CACGCATGCA GTTCAACCTG TTGATAGTAC

30

(2) INFORMATION FOR SEQ ID NO:45:

(i) SEQUENCE CHARACTERISTICS:

20 (A) LENGTH: 28 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

25 (ii) MOLECULE TYPE: other nucleic acid

(A) DESCRIPTION: /desc = "primer"

30 (iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

35 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:45:

GCGTCTAGAT CCTTTAAAT TAAAAATG

28

40 **Claims**

1. A method for the production of glycerol from a recombinant organism comprising:

45 (i) transforming a suitable host cell with an expression cassette comprising

(a) a gene encoding a protein having glycerol-3-phosphate dehydrogenase activity, and
 (b) a gene encoding a protein having glycerol-3-phosphate phosphatase activity,

50 the suitable host cell having a disruption in

(a) an endogenous gene encoding a polypeptide having glycerol kinase activity, and
 (b) optionally, an endogenous gene encoding a polypeptide having glycerol dehydrogenase activity,

55 wherein the disruption prevents the expression of active gene product;

(ii) culturing the transformed host cell of (i) in the presence of at least one carbon source selected from the group consisting of monosaccharides, oligosaccharides, polysaccharides, and single-carbon substrates, whereby glycerol is produced; and

(iii) optionally recovering the glycerol produced in (ii).

2. The method of Claim 1 wherein the host cell contains a disruption in a gene encoding an endogenous glycerol dehydrogenase enzyme wherein the disruption prevents the expression of active gene product.

5 3. The method of Claim 1 wherein the suitable host cell is selected from the group consisting of bacteria, yeast, and filamentous fungi.

10 4. The method of Claim 3 wherein the suitable host cell is selected from the group consisting of *Citrobacter*, *Enterobacter*, *Clostridium*, *Klebsiella*, *Aerobacter*, *Lactobacillus*, *Aspergillus*, *Saccharomyces*, *Schizosaccharomyces*, *Zygosaccharomyces*, *Pichia*, *Kluyveromyces*, *Candida*, *Hansenula*, *Debaryomyces*, *Mucor*, *Torulopsis*, *Methylobacter*, *Escherichia*, *Salmonella*, *Bacillus*, *Streptomyces*, and *Pseudomonas*.

15 5. The method of Claim 4 wherein the suitable host cell is *E. coli* or *Saccharomyces* sp.

6. The method of Claim 1 wherein the carbon source is glucose.

20 7. The method of Claim 1 wherein the protein having glycerol-3phosphate dehydrogenase activity corresponds to amino acid sequences selected from the group consisting of SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO: 10, SEQ ID NO:11, and SEQ ID NO: 12 and wherein the amino acid sequences encompasses amino acid substitutions, deletions or insertions that do not alter the functional properties of the enzyme.

25 8. The method of Claim 1 wherein the protein having glycerol-3-phosphate phosphatase activity corresponds to the amino acid sequences selected from the group consisting of SEQ ID NO: 13 and SEQ ID NO: 14, and wherein the amino acid sequences may encompass amino acid substitutions, deletions or additions that do not alter the function of the enzyme.

25 9. A transformed host cell comprising:

30 (a) a gene encoding a protein having a glycerol-3-phosphate dehydrogenase activity;

(b) a gene encoding a protein having glycerol-3-phosphate phosphatase activity;

35 (c) a disruption in a gene encoding an endogenous glycerol kinase and optionally, a disruption in a gene encoding an endogenous glycerol dehydrogenase;

wherein the disruptions in the gene or genes of (c) prevent the expression of active gene product, and wherein the host cell converts at least one carbon source selected from the group consisting of monosaccharides, oligosaccharides, polysaccharides, and single-carbon substrates to glycerol.

40 10. A method for the production of 1,3-propanediol from a recombinant organism comprising:

(i) transforming a suitable host cell with an expression cassette comprising

40 (a) a gene encoding a protein having glycerol-3-phosphate dehydrogenase activity, and
(b) a gene encoding a protein having glycerol-3-phosphate phosphatase activity,

45 the suitable host cell having at least one gene encoding a protein having a dehydratase activity and having a disruption in :

(a) an endogenous gene encoding a polypeptide having glycerol kinase activity, and
(b) optionally, an endogenous gene encoding a polypeptide having glycerol dehydrogenase activity,

50 wherein the disruption in the genes of (a) or (b) prevents the expression of active gene product;

(ii) culturing the transformed host cell of (i) in the presence of at least one carbon source selected from the group consisting of monosaccharides, oligosaccharides, polysaccharides, and single-carbon substrates whereby 1,3propanediol is produced; and

(iii) recovering the 1,3-propanediol produced in (ii).

55 11. The method of Claim 10 wherein the protein having a dehydratase activity is selected from the group consisting of a glycerol dehydratase enzyme and a diol dehydratase enzyme.

12. The method of Claim 11 wherein the glycerol dehydratase enzyme is encoded by a gene, the gene isolated from a microorganism, the microorganism selected from the group consisting of *Klebsiella*, *Laciobacillus*, *Enterobacter*, *Citrobacter*, *Pelobacter*, *Ilyobacter*, and *Clostridium*.

5 13. The method of Claim 11 wherein the diol dehydratase enzyme is encoded by a gene, the gene isolated from a microorganism, the microorganism selected from the group consisting of *Klebsiella* and *Salmonella*.

Patentansprüche

10 1. Verfahren für die Herstellung von Glycerol aus einem rekombinanten Organismus, umfassend:

(i) Transformieren einer geeigneten Wirtszelle mit einer Expressionskassette, umfassend

15 (a) ein Gen, codierend ein Protein mit Glycerol-3-phosphat-Dehydrogenase-Aktivität, und
 (b) ein Gen, codierend ein Protein mit Glycerol-3-phosphat-Phosphatase-Aktivität,
 wobei die geeignete Wirtszelle eine Disruption in

20 (a) einem endogenen Gen, codierend ein Polypeptid mit Glycerol-Kinase-Aktivität, und
 (b) gegebenenfalls einem endogenen Gen, codierend ein Polypeptid mit Glycerol-Dehydrogenase-Aktivität,
 hat, wobei die Disruption die Expression von aktivem Genprodukt verhindert;

25 (ii) Kultivieren der transformierten Wirtszelle von (i) in Anwesenheit von mindestens einer Kohlenstoffquelle, ausgewählt aus der Gruppe, bestehend aus Monosacchariden, Oligosacchariden, Polysacchariden und Ein-Kohlenstoff-Substraten, wodurch Glycerol erzeugt wird; und
 (iii) gegebenenfalls Gewinnen des in (ii) erzeugten Glycerols.

30 2. Verfahren nach Anspruch 1, wobei die Wirtszelle eine Disruption in einem Gen, codierend ein endogenes Glycerol-Dehydrogenase-Enzym, enthält, wobei die Disruption die Expression von aktivem Genprodukt verhindert.

35 3. Verfahren nach Anspruch 1, wobei die geeignete Wirtszelle aus der Gruppe, bestehend aus Bakterien, Hefe und Fadenpilzen, ausgewählt ist.

40 4. Verfahren nach Anspruch 3, wobei die geeignete Wirtszelle aus der Gruppe, bestehend aus *Citrobacter*, *Enterobacter*, *Clostridium*, *Klebsiella*, *Aerobacter*, *Lactobacillus*, *Aspergillus*, *Saccharomyces*, *Schizosaccharomyces*, *Zygosaccharomyces*, *Pichia*, *Kluyveromyces*, *Candida*, *Hansenula*, *Debaryomyces*, *Mucor*, *Torulopsis*, *Methylobacter*, *Escherichia*, *Salmonella*, *Bacillus*, *Streptomyces* und *Pseudomonas*, ausgewählt ist.

45 5. Verfahren nach Anspruch 4, wobei die geeignete Wirtszelle *E. coli* oder *Saccharomyces* sp. ist.

6. Verfahren nach Anspruch 1, wobei die Kohlenstoffquelle Glucose ist.

50 7. Verfahren nach Anspruch 1, wobei das Protein mit Glycerol-3-phosphat-Dehydrogenase-Aktivität Aminosäuresequenzen, ausgewählt aus der Gruppe, bestehend aus SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11 und SEQ ID NO:12, entspricht und wobei die Aminosäuresequenzen Aminosäuresubstitutionen, -deletionen oder -insertionen einschließen, die die funktionellen Eigenschaften des Enzyms nicht verändern.

55 8. Verfahren nach Anspruch 1, wobei das Protein mit Glycerol-3-Phosphat-Phosphatase-Aktivität den Aminosäuresequenzen, ausgewählt aus der Gruppe, bestehend aus SEQ ID NO:13 und SEQ ID NO:14, entspricht und wobei die Aminosäuresequenzen Aminosäuresubstitutionen, -deletionen oder -additionen einschließen können, die die Funktion des Enzyms nicht verändern.

9. Transformierte Wirtszelle, umfassend:

(a) ein Gen, codierend ein Protein mit einer Glycerol-3-phosphat-Dehydrogenase-Aktivität;
 (b) ein Gen, codierend ein Protein mit Glycerol-3-phosphat-Phosphatase-Aktivität;

(c) eine Disruption in einem Gen, codierend eine endogene Glycerol-Kinase, und gegebenenfalls eine Disruption in einem Gen, codierend eine endogene Glycerol-Dehydrogenase;

5 wobei die Disruptionen in dem Gen oder den Genen von (c) die Expression von aktivem Genprodukt verhindern und wobei die Wirtszelle mindestens eine Kohlenstoffquelle, ausgewählt aus der Gruppe, bestehend aus Monosacchariden, Oligosacchariden, Polysacchariden und Ein-Kohlenstoff-Substraten, in Glycerol umwandelt.

10. Verfahren für die Herstellung von 1,3-Propandiol aus einem rekombinanten Organismus, umfassend:

10 (i) Transformieren einer geeigneten Wirtszelle mit einer Expressionskassette, umfassend

(a) ein Gen, codierend ein Protein mit Glycerol-3-phosphat-Dehydrogenase-Aktivität, und
(b) ein Gen, codierend ein Protein mit Glycerol-3-phosphat-Phosphatase-Aktivität,

15 wobei die geeignete Wirtszelle mindestens ein Gen, codierend ein Protein mit einer Dehydratase-Aktivität, hat und eine Disruption in

(a) einem endogenen Gen, codierend ein Polypeptid mit Glycerol-Kinase-Aktivität, und
(b) gegebenenfalls einem endogenen Gen, codierend ein Polypeptid mit Glycerol-Dehydrogenase-Aktivität,

20 hat, wobei die Disruption in den Genen von (a) oder (b) die Expression von aktivem Genprodukt verhindert;
(ii) Kultivieren der transformierten Wirtszelle von (i) in Anwesenheit von mindestens einer Kohlenstoffquelle, ausgewählt aus der Gruppe, bestehend aus Monosacchariden, Oligosacchariden, Polysacchariden und Ein-Kohlenstoff-Substraten, wodurch 1,3-Propandiol erzeugt wird; und
(iii) Gewinnen des in (ii) erzeugten Glycerols.

25 11. Verfahren nach Anspruch 10, wobei das Protein mit einer Dehydratase-Aktivität aus der Gruppe, bestehend aus einem Glycerol-Dehydratase-Enzym und einem Diol-Dehydratase-Enzym, ausgewählt ist.

30 12. Verfahren nach Anspruch 11, wobei das Glycerol-Dehydratase-Enzym durch ein Gen codiert ist, das Gen aus einem Mikroorganismus isoliert ist, der Mikroorganismus aus der Gruppe, bestehend aus *Klebsiella*, *Lactobacillus*, *Enterobacter*, *Citrobacter*, *Pelobacter*, *Ilyobacter* und *Clostridium*, ausgewählt ist.

35 13. Verfahren nach Anspruch 11, wobei das Diol-Dehydratase-Enzym durch ein Gen codiert ist, das Gen aus einem Mikroorganismus isoliert ist, der Mikroorganismus aus der Gruppe, bestehend aus *Klebsiella* und *Salmonella*, ausgewählt ist.

40 **Revendications**

1. Procédé pour la production de glycérol à partir d'un organisme recombinant consistant à:

45 (i) transformer une cellule hôte adaptée avec une cassette d'expression comprenant

(a) un gène codant pour une protéine ayant une activité glycérol-3-phosphate déshydrogénase, et
(b) un gène codant pour une protéine ayant une activité glycérol-3-phosphate phosphatase,
la cellule hôte adaptée ayant une interruption dans

50 (a) un gène endogène codant pour un polypeptide ayant une activité glycérol kinase, et
(b) éventuellement, un gène endogène codant pour un polypeptide ayant une activité glycérol déshydrogénase,

55 dans laquelle l'interruption empêche l'expression de produit de gène actif;
(ii) mettre en culture la cellule hôte transformée de (i) en présence d'au moins une source de carbone sélectionnée dans le groupe constitué de monosaccharides, oligosaccharides, polysaccharides, et substrats à un seul carbone, à partir de laquelle le glycérol est produit; et
(iii) éventuellement récupérer le glycérol produit en (ii).

2. Procédé selon la revendication 1 dans lequel la cellule hôte contient une interruption dans un gène codant pour une enzyme glycérol déshydrogénase endogène dans lequel l'interruption empêche l'expression de produit de gène actif.

5 3. Procédé selon la revendication 1 dans lequel la cellule hôte adaptée est sélectionnée dans le groupe constitué de bactéries, levures, champignons filamenteux.

4. Procédé selon la revendication 3 dans lequel la cellule hôte adaptée est sélectionnée dans le groupe constitué de *Citrobacter*, *Enterobacter*, *Clostridium*, *Klebsiella*, *Aerobacter*, *Lactobacillus*, *Aspergillus*, *Saccharomyces*, *Schizosaccharomyces*, *Zygosaccharomyces*, *Pichia*, *Kluyveromyces*, *Candida*, *Hansenula*, *Debaryomyces*, *Mucor*, *Torulopsis*, *Methylobacter*, *Escherichia*, *Salmonella*, *Bacillus*, *Streptomyces*, et *Pseudomonas*.

10 5. Procédé selon la revendication 4 dans lequel la cellule hôte adaptée est *E. coli* ou *Saccharomyces sp.*

15 6. Procédé selon la revendication 1 dans lequel la source de carbone est du glucose.

7. Procédé selon la revendication 1 dans lequel la protéine ayant une activité glycérol-3-phosphate déshydrogénase correspond aux séquences d'acides aminés sélectionnées dans le groupe constitué de SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 et SEQ ID NO: 12 et dans lequel les séquences d'acides aminés incluent des substitutions, des délétions ou des insertions d'acides aminés qui ne modifient pas les propriétés fonctionnelles de l'enzyme.

20 8. Procédé selon la revendication 1 dans lequel la protéine ayant une activité glycérol-3-phosphate phosphatase correspond aux séquences d'acides aminés sélectionnées dans le groupe constitué de SEQ ID NO: 13 et SEQ ID NO: 14, et dans lequel les séquences d'acides aminés peuvent inclure des substitutions, des délétions ou des additions d'acides aminés qui ne modifient pas la fonction de l'enzyme.

25 9. Cellule hôte transformée comprenant:

30 (a) un gène codant pour une protéine ayant une activité glycérol-3-phosphate déshydrogénase;

(b) un gène codant pour une protéine ayant une activité glycérol-3-phosphate phosphatase;

(c) une interruption dans un gène codant pour une glycérol kinase endogène et éventuellement une interruption dans un gène codant pour une glycérol déshydrogénase endogène;

35 dans laquelle les interruptions dans le gène ou les gènes de (c) empêchent l'expression de produit de gène actif, et dans laquelle la cellule hôte transforme en glycérol au moins une source de carbone sélectionnée dans le groupe constitué de monosaccharides, oligosaccharides, polysaccharides, et substrats à un seul carbone.

40 10. Procédé pour la production de 1,3-propanediol à partir d'un organisme recombinant consistant à:

(i) transformer une cellule hôte adaptée avec une cassette d'expression comprenant

45 (a) un gène codant pour une protéine ayant une activité glycérol-3-phosphate déshydrogénase, et

(b) un gène codant pour une protéine ayant une activité glycérol-3-phosphate phosphatase,

la cellule hôte adaptée ayant au moins un gène codant pour une protéine ayant une activité déshydratase et ayant une interruption dans:

50 (a) un gène endogène codant pour un polypeptide ayant une activité glycérol kinase, et

(b) éventuellement, un gène endogène codant pour un polypeptide ayant une activité glycérol déshydrogénase,

dans laquelle l'interruption dans les gènes de (a) ou (b) empêche l'expression de produit de gène actif;

55 (ii) mettre en culture la cellule hôte transformée de (i) en présence d'au moins une source de carbone sélectionnée dans le groupe constitué de monosaccharides, oligosaccharides, polysaccharides, et substrats à un seul carbone, à partir de laquelle du 1,3-propanediol est produit; et

(iii) récupérer le 1,3-propanediol produit dans (ii).

11. Procédé selon la revendication 10 dans lequel la protéine ayant une activité déshydratase est sélectionnée dans le groupe constitué d'une enzyme glycérol déshydratase et d'une enzyme diol déshydratase.

5 12. Procédé selon la revendication 11 dans lequel l'enzyme glycérol déshydratase est codée par un gène, le gène isolé à partir d'un microorganisme, le microorganisme sélectionné dans le groupe constitué de *Klebsiella*, *Lactobacillus*, *Enterobacter*, *Citrobacter*, *Pelobacter*, *Ilyobacter*, et *Clostridium*.

13. Procédé selon la revendication 11 dans lequel l'enzyme diol déshydratase est codée par un gène, le gène isolé à partir d'un microorganisme, le microorganisme sélectionné dans le groupe constitué de *Klebsiella*, et *Salmonella*.

10

15

20

25

30

35

40

45

50

55